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ABSTRACT 
Background: Improving wait times has become a national priority and prostate cancer 
wait times have not been studied in Newfoundland and Labrador (NL). 
Methods: Using a retrospective chart review, we measured and compared wait times for 
prostate cancer care to benchmarks set by local, national, and international experts. 
Residents who had a prostate biopsy between April I, 2009 - March 3I , 20 I 0 at the 
Health Science Centre in St. John' s, NL were eligible. 
Results: The 34I eligible patients experienced the longest median wait of 68 days (0-
3I 0) between general practitioner date of referral to first visit with urologist. Few men 
met the established benchmarks for suspected prostate cancer care. Delays were not 
uncommon, and most often existed between date ofbiopsy and notification of results. 
Conclusion: Few men met local and national wait time benchmarks for prostate cancer 
care. Findings can be used to identify strategies to improve the timeliness of specialist 
care in NL and to enhance the reliability of wait times research. 
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CHAPTER 1 
INTRODUCTION 
1.1 Background 
Prostate cancer has a higher incidence rate in Canadian men than any other cancer 
(Canadian Cancer Statistics, 2011). In 2011, it was anticipated that 122 per 100 000 
Canadian men would be diagnosed with prostate cancer and an estimated 21 per 100 000 
men would potentially die from it. Atlantic Canada has been shown to have a higher 
incidence rate of prostate cancer than the rest of Canada (Canadian Cancer Statistics, 
2011). 
In 2011 , Newfoundland and Labrador (NL) had an expected incidence rate for 
prostate cancer of 119 per 100 000 men and at least 29 per 100 000 men were expected to 
die from the disease (Canadian Cancer Statistics, 2011). These are considered to be 
underestimates due to the variability in the reporting of data from the province. 
Although timely access is believed to be one of the keys in reducing morbidity 
and mortality related to prostate cancer (Saad et al., 2006), appropriate wait times or 
benchmarks have not been established for prostate cancer. To date, there have been few 
studies that have examined wait times for prostate cancer care in Canada and none in NL. 
1.2 Research Goals and Objectives 
This study will describe wait times for prostate cancer care provided by urologists 
located in St. John's, NL. The specific objectives of the study are: 
1. to use chart audit data to measure the wait time intervals for patients with 
suspected or confirmed prostate cancer in NL. Specific intervals of wait time 
will be described, including those related to elapsed time between: (a) general 
practitioner1 (GP) referral to first visit with an urologist; (b) decision to biopsy 
to date of biopsy; (c) date of biopsy to when the pathology report is received 
by the urologist; (d) date pathology report received to when the patient is 
informed; and (e) decision to treat to date of first treatment. 
2. to examine differences in wait times for men who met and did not meet 
locally established benchmarks which are related to the following 
characteristics: community of residence (urban/rural), urgency (non-urgent 
and urgent symptoms) , and age (young -less than 70 years of age and old -
over 70 years of age). 
This study will test the following hypotheses: 
a. the longest wait interval will occur between the general practitioner referral 
and first visit with urologist. 
b. variations in intervals and total wait times will be related to place of 
residence, stage of disease, and the age of the patient. Rural, older ( -;80 
years), and non-urgent patients will wait longer than urban, younger and 
urgent prostate cancer patients, respectively. 
1.3 Rationale 
In 1998, Macdonald et al. outlined many problems surrounding the management 
of wait times and made recommendations for improving the management of health 
services. They found that "with few exceptions Canada's waiting lists are non-
standardized, capriciously organized, poorly monitored, and (according to most informed 
1 The terms family physician, family practitioner, and general practitioner are used 
interchangeably despite the differences in credentialing. 
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observers) in grave need of retooling" (Macdonald et al., 1998, pg.i). Improving wait 
times in Canada is an important issue to Canadians and Health Canada has made 
researching Canada's wait times a national priority (Health Canada, 2004). 
In September 2004, Canada's First Ministers created a 10-Year Plan to Strengthen 
Health Care in which the First Ministers planned to target organization of wait times and 
reduce waits in five key areas: (a) heart; (b) diagnostics; (c) hip and knee replacement; (d) 
sight restoration; and (e) cancer. To do this, the plan provided targets for improving 
waiting times by: 
1. establishing comparable wait time data by the end of2005. 
2. providing evidence-based benchmarks by the end of2005. 
3. having each province and territory reporting their wait time data and progress in 
meeting the wait time targets by the end of 2007 (Health Canada, 2004 ). 
While there have been improvements in reducing wait times for health care 
services in Canada since the First Ministers met in 2004, the problem is far from being 
solved. Multiple lists still exist, the reporting of how long people are waiting and for what 
service is lacking, and efforts to make the data comparable are far from complete 
(Canadian Institute for Health Information [CIHI] , 2006). In order to show the public 
whether wait times are improving or not, provinces and territories need a baseline 
measurement. They also need to report data collected from across their jurisdictions 
consistently to demonstrate their progress, or lack thereof (Health Council of Canada 
[HCC], 2007). 
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This study is important because it helps address the national health priorities 
outlined by Health Canada's 10-year Plan to Strengthen Health Care in Canada. 
Specifically, this study will: 
1. provide reliable and accurate baseline data regarding specific patient wait times 
for prostate cancer care in NL. 
2. aid in identifying the unacceptable or unsatisfactory intervals of wait for 
prostate cancer patients in NL. 
This study will begin to collect data on prostate cancer wait times and describe 
how long those patients are waiting for each service. Hence, this project will provide 
baseline data to help access the performance of the prostate cancer care system and 
identify potential future interventions aimed at reducing waiting times for prostate cancer 
care. It will also contribute to the body of knowledge around data and methodological 
challenges associated with wait times research. 
The results of this project are relevant to cancer care providers (urologists and 
oncologists), the Department of Health and Community Services, cancer advocacy 
groups (prostate cancer support groups), patients and their families, and clinical and 
health services researchers. 
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CHAPTER2 
LITERATURE REVIEW 
This literature review is organized into two main sections. In the first section, the 
disease of prostate cancer is introduced and described, and current methods of detection, 
staging and treatment are outlined. In the second section, the issue of wait times for health 
care is discussed in terms of definitions and factors impacting wait times, followed by a 
review of challenges associated with measuring wait times for cancer care generally and 
prostrate cancer specifically. 
2.1 Prostate Cancer: 
2.1.1 The Disease 
The prostate, as shown in Figure 2.1, is part of the male reproductive system and 
produces seminal fluid to make semen. The size of the prostate gland is walnut sized and is 
found underneath the penis next to the urethra (Canadian Cancer Society [CCS] , 201 0) . 
urethra .... _,._,n 
penis 
...... ~~-e redum 
~'-""-.,_ .. pro~tate 
..--......... " 
i-__ .....,_...,. testicle 
Figure 2. 1 : The prostate. Borrowed with permission from the Canadian Cancer Society. 
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Prostate cancer is one of several types of cancers that may develop in the body. 
Some commonalities exist between the many different cancers. Cancer cells grow without 
controls and limits; they keep growing and can spread and overwhelm the body. Prostate 
cancer can be defined by the uncontrolled growth of the glandular cells located within the 
prostate (Marks, 1999). These cells typically produce fluid that make up part of the semen. 
In most situations, prostate cancer is a slow growing cancer, although, there are 
instances where prostate cancer can grow very rapidly and become deadly. There are 
groups of males that are more likely to develop prostate cancer than others. Ifthere is a 
family history of prostate cancer, it is reasonable to assume the risk is higher for developing 
prostate cancer (Marks, 1999). Prostate cancer is also associated with older age; as the 
population ages more prostate cancer is usually detected. Even though the risk of prostate 
cancer diagnoses grows as men age, many can live with undiagnosed prostate cancer only 
to pass away from another disease (Ilic, O'Connor, Green, & Wilt, 2006). 
Prostate cancer symptoms consist of: (a) the need to urinate often; (b) difficulty 
urinating; (c) semen and blood found in urine; (d) burning sensation during urination; (e) 
urine flow problems; and (f) painful ejaculation (CCS, 201 0). Prostate cancer can remain 
asymptomatic for many males and may be discovered through screening methods such as 
the prostate specific antigen (PSA) test or the digital rectal exam (DRE). However, 
symptoms can begin to appear when a tumor begins to grow and affect the flow of urine. 
Typically, as men age and grow older, prostate cancer symptoms can begin to become 
noticeable; however, these symptoms can also be related to a common condition known as 
6 
benign prostatic hyperplasia (BPH). Due to the similarities between both prostate cancer 
and BPH, diagnostic testing is necessary. 
2.1.2 Detection Methods 
A screening test is a test for a certain disease given to individuals who are 
asymptomatic. Individuals with a history of prostate cancer in their family are 
recommended to undergo annual screening tests, such as a ORE and PSA test starting by 
the age of 40 (Marks, 1999). These screening tests intend to diminish disease-specific 
morbidity and mortality by detecting prostate cancer earlier and more often (Marks, 1999). 
2.1.2.1 The Digital Rectal Exam (ORE) 
A ORE is performed to check for problems with the prostate and/or the urology 
tract. During the examination, a physician uses a gloved finger of one hand to enter the 
rectum to feel for abnormalities on the prostate gland. A prostate tumor can usually be felt 
as a hard or boggy lump (Marks, 1999). Most often, the DRE is used together with a PSA 
test and is not used alone to screen for prostate cancer. Any abnormality in the DRE and 
PSA can reflect symptoms of other common conditions like BPH. Furthermore, the 
physician can miss abnormalities in the ORE because the tumor can grow on the opposite 
side of the prostate that cannot be palpated. 
2.1.2.2 The Prostate Specific Antigen Test (PSA) 
The PSA test is a blood test that may help detect prostate cancer by measuring 
prostate specific antigen quantities created by the prostate. While it is typical to find small 
quantities ofPSA in the blood, problems with the prostate can cause increases in blood 
PSA (CCS, 201 0). PSA levels can also change with age, increase gradually and can be 
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attributed to other known conditions such as BPH, urinary infection, or a recent prostate 
biopsy (Nam and Klotz, 2009). However, men with prostate cancer can still have normal 
PSA levels. 
While the aim of PSA screening for prostate cancer is to improve the survival rates 
and increase the quality of life, there is little consensus on the effectiveness of such 
screening. The Cochrane Review of prostate cancer screening found that the PSA test 
discovered prostate cancer more often than not, but did not reduce prostate cancer death 
(Ilic et al., 2006). 
In 2009, two landmark studies were published in the New England Journal of 
Medicine that examined strategies for incorporating the PSA test for screening purposes. 
The first study was a large randomized control study based in the United States which 
involved 76 693 men from the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer 
screening trial. Subjects were randomly assigned to one of two groups: either an annual 
PSA screening group (in addition to prostate examinations) or a no screening (control) 
group. The primary outcome in the study was death because of prostate cancer. After 
completing a 7-year follow-up, the PLCO study found that the incidence of mortality was 
not significantly different between the screening and control groups (2.0 per 10 000 person-
years in the screening group and 1. 7 per 1 0 000 in the control group; rate ratio, 1.13; 95% 
CI, 0.75 to 1.70 (Andriole et al., 2009). 
The European Randomized Study of Screening for Prostate Cancer (ERSPC) 
included 162 243 men. These men were randomly assigned to a group that was offered 
PSA screening at an average of once every four years or to a control group that did not 
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receive such screening. The age group for this study included men between the ages of 55 
and 69 years. The primary outcome was the rate of death from prostate cancer. The study 
found that the ratio of death from prostate cancer in the screening group compared to the 
control group was 0.80 (95% CI, 0.65 to 0.98; adjusted P = 0.04). Although the PSA test 
reduced the rate of death from prostate cancer by 20%, it was associated with a high risk of 
over diagnosis. 
Due to the conflicting results from these studies the medical community continues 
to debate the role ofPSA testing (Schroder eta!. , 2009). Comparing these two studies it is 
important to point out some potential critiques. First, the PLCO study had 44% of all 
patients undergoing PSA testing before entering the study, which eliminated patients with 
aggressive prostate cancer whose death may have been prevented by screening. 
Furthermore, only 40% of the patients had a prompt biopsy when their PSA went up, and 
52% of the controls had PSA testing. These choices may have lead to a lack of evidence 
supporting a mortality benefit for annual PSA screening. 
Currently the U.S. Preventive Services Task Force (USPSTF) recommends against 
PSA-based screening for prostate cancer given the benefits don't outweigh the harms. This 
recommendation applies to men in the general U.S. population, regardless of age. This 
recommendation does not include the use of the PSA test for surveillance after diagnosis or 
treatment of prostate cancer; the use of the PSA test for this indication is outside the scope 
of the USPSTF (U.S. Preventive Services Task Force, 2012). 
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2.1.2.3 The Transrectal Ultrasound (TRUS) Biopsy 
If the PSA test and DRE suggest the possibility of prostate cancer, it is necessary to 
have a biopsy to determine the presence of cancer. Prostate biopsies guided by a transrectal 
ultrasound (TRUS) are performed to confirm diagnoses. The biopsy consists of a core 
needle guided by a TRUS penetrating the wall of the rectum into the prostate gland (ACS, 
2009). The needle obtains a sample of the prostate, which is then examined for cancerous 
cells by a pathologist. Typically, eight to 18 core samples are taken; most urologists in NL 
take 12 samples (Dr. Chris French, personal communication, February, 2009). 
2.1.3 Staging 
From the biopsy, the grade of the cancer is determined using the Gleason scoring 
system. According to So & Goldberg, Gleason grading assesses "prostate glandular 
architecture rather than cytological morphology" (pg. 24, 2004). The grade of the cancer 
indicates the nature of the cancer and its potential behavior by comparing prostate cancer 
cells to normal cells in the prostate (Marks, 1999). Gleason score is considered to be the 
best method of grading, because this method examines the heterogeneity of prostate cancer, 
and has demonstrated the greatest prognostic value (American Joint Committee on Cancer 
Staging [AJCC], 2012). 
The Gleason score or Gleason sum is obtained by adding the primary and secondary 
grades together. As Gleason scores range from one to five, therefore they can range from 2 
to 10. Well-differentiated tumors have a Gleason sum of 2-4, moderately differentiated 
tumors have a Gleason sum of 5-6, and poorly differentiated tumors have a Gleason sum of 
8- 10. Gleason score can be classified by: (a) 6 or less as low-risk; (b) 7 as intermediate-
10 
risk; and (c) 8 or above as high-risk. Gleason 7 tumors can be further stratified into either 
3+4 or 4+ 3 positive cores, depending on which grade is most common in the biopsy cores 
(Epstein, 2011; So & Goldberg, 2004; D'amico et al., 1998). According to Dr. Chris 
French, this approach to Gleason scoring is used by urologists in St. John's, NL (personal 
communication, 2012). 
Staging describes the progression of an individual's cancer. Knowing the stage of 
the disease can help patients and urologists plan treatment options and estimate prognoses. 
A common system for urologists describing the stage of cancer is the Tumor Node 
Metastasis (TNM) system: T describes tumor size, how much of the prostate it occupies, 
and its involvement with other tissue, N describes if any lymph node involvement, and M 
describes metastasis or the movement of cancer from one area of the body to another. 
Table 2.1 further describes how the staging of prostate cancer takes place (National Cancer 
Institute, 201 0; AJCC, 2012). For example, prostate cancer described as T2c NO MO means 
the tumor is in both lobes but is still inside the prostate gland, with no cancer spreading to 
the lymph nodes, and no cancer spreading outside areas outside of the pelvis. 
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Table 2.1: TNM Staging System According to the American Joint Committee on Cancer 
Staging 
Staging Description 
Tl The tumor is too small to be seen on scans or felt during examination of the prostate 
T2 The tumor is completely inside the prostate gland 
T2a The tumor is in only half of one of the lobes of the prostate gland 
T2b The tumor is in more than half of one of the lobes 
T2c The tumor is in both lobes but is still inside the prostate gland 
T3 The tumor has broken through the capsule (covering) of the prostate gland 
T4 The tumor has spread into other body organs nearby, such as the rectum (back passage) or bladder 
NO No cancer cells found in any lymph nodes 
Nl One positive lymph node smaller than 2cm across 
N2 More than one positive lymph node. Or one that is between 2 and Scm across 
N3 Any positive lymph node that is bigger than 5 em across 
MO No cancer has spread outside the pelvis 
Ml Cancer has spread outside the pelvis 
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Staging of cancer can be separated into two distinct areas: clinical and pathological. 
Clinical staging identifies how much cancer is present based on physical examination, 
diagnostics, and biopsies of the prostate. Clinical staging is used by the urologist to 
triage and treat patients until pathological staging is available. Pathological staging of 
cancer occurs only for patients who have surgery to take out the affected tissue and 
explore the extent of the cancer. Pathological staging considers the physical examination, 
imaging tests, and the surgical results (AJCC, 2010). The clinical stage of cancer will be 
used in this study as it best reflects current urological practice. The Canadian Surgical 
Wait Times (SWAT) Initiative (2006) suggests that when treating prostate cancer, it is 
best practice to triage patients based on risk: 
1. a high-risk patient will have a PSA greater than 20 ng/ml, Gleason score greater 
than 7, and/or T3b. 
2. a intermediate risk patient will have a PSA between 10 and 20 ng/ml, a Gleason 
score of seven, or T2b, T3a. 
3. a low-risk patient will have a PSA less than 10 ng/ml, Gleason score less than 
seven, and a clinical stage of cancer ofT 1-T2a. 
2.1.4 Treatment Options 
There are many different treatment options available for treating prostate cancer 
and the right treatment depends on age, Gleason score, stage, symptoms, and the general 
health of the patient. Treatment options mainly include: (a) active surveillance (watchful 
waiting); (b) surgery; (c) radiation therapy; (d) hormone therapy; and (e) chemotherapy. 
It is possible that prostate cancer may not require treatment as soon as it is diagnosed and 
13 
an active surveillance approach may be deemed appropriate. This approach allows 
patients to avoid potential side effects or other treatments such as erectile dysfunction or 
bladder control (CCS, 201 0). Patients would expect to have regular PSA tests, rectal 
examinations, and/or a repeat biopsy, which may suggest a change in the growth of the 
prostate cancer. (Dr. Chris French, personal communication, February, 201 0). 
2.1.4.1 Surgery 
If the cancer is only found within the prostate and has not spread having surgery 
to remove the prostate can be one of the best options for cure. This treatment option is 
common for men who are under the age of70, in good health, and have a stage ofT1 or 
T2, or a small T3 cancer tumor. At the time of surgery, the surgeon may remove some 
lymph nodes proximal to the prostate to examine if the cancer has spread. The surgery 
may be performed in a number of different ways including robotic assistance, the use of a 
scope, or open surgery. Special techniques may be used during surgery to help spare the 
nerves in maintaining erections. Surgery can produce side effects such as impotence 
and/or the inability to control urine flow (incontinence). Therefore, different surgical 
techniques are offered, depending on the progression of the cancer and the potential for 
side effects such as loss ofbladder control, erectile dysfunction, narrowing of the urethra, 
and bleeding or infection (National Cancer Institute, 2013; CCS, 201 0). 
2.1.4.2 Radiation 
There are two types of radiation techniques used to treat and/or manage prostate 
cancer: external beam radiation (EBR) and brachytherapy (National Cancer Institute, 
2013 ; Marks, 1999). EBR is high-energy x-ray beams that are directed at mens' prostate 
tumours to destroy cancer cells. This involves using a three-dimensional conformal 
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treatment plan with intensity-modulated radiation therapy (IMRT) to maximize the dose 
to the prostate while minimizing damage to adjacent structures. EBR still remains the 
standard of care in many settings and may be offered to men for a potential cure, low or 
medium-grade cancers who would not be considered for surgery due to other health 
problems, adjuvant therapy, or in advanced cases to control the progression of the cancer 
or palliative care (National Cancer Institute, 2013 ; CCS, 2010). 
Postoperative EBR has been used to improve local-regional control by eliminating 
microscopic residual tumor in the area where surgery was perfonned, surrounding 
prostatic tissues, and bordering lymph nodes. Many patients may be offered postoperative 
EBR ifthey are found to have: (a) cancer found on the margins of the prostate; (b) 
seminal vesicle involvement; (c) lymph node involvement, (d) extracapsular extension; 
(e) rising PSA; and (f) recurrence of the cancer found by biopsy. These variables have 
been associated with biochemical recurrence (National Cancer Institute, 2013). 
Brachytherapy involves implanting radioactive, rice-sized seeds in the prostate. 
The seeds release radiation, killing the cancerous cells. The dose and length of treatment 
depends on the treating physician and the specific case of cancer. This treatment may be 
offered to men who have early-stage prostate cancer with small prostates or to men with 
large prostates after hormone therapy or in conjunction with EBR. One popular 
advantage with this form of radiation is the ability to deliver a very high dose of radiation 
to a localized area with a decreased number of treatment visits (National Cancer Institute, 
2013; CCS, 2010). 
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2.1.4.3 Chemotherapy 
Chemotherapy uses medication to destroy cancer cells or help prevent them from 
growing. One problem is that chemotherapy may also damage normal cells. In men with 
advanced-staged prostate cancer, chemotherapy may help the progression of the cancer, 
prolong life, and relieve pain that may occur further in the disease course. This treatment 
is usually not offered to men who have early-stage disease. However, chemotherapy is 
offered to men whose cancer has returned or has spread to another area of the body and is 
considered treatment of choice when there is progression of disease despite low levels of 
testosterone (castration-resistant prostate cancer) (National Cancer Institute, 2013; Maluf, 
Smaletz, & Herchenhom, 20 12). 
2.1.4.4 Hormone Therapy 
Endocrine or hormone therapy blocks the body' s production of androgens, which 
are steroid compounds that produce the male characteristics (CCS, 201 0). Endocrine 
therapy is not a cure, but data exists to suggest that it may decrease cancer growth in 70-
85% of patients (CCS, 201 0). The most common types of endocrine therapies are: (a) 
luteinizing hormonal therapies (LHRH antagonists/agonists); (b) anti-androgens; and (c) 
orchiectomy surgery (removal of the testicles). This treatment is most often offered to 
men whose cancer has spread outside the prostate, who have high-risk of cancer 
recurrence after radiotherapy or surgery, or for men who are not suitable candidates for 
surgery or radiation (National Cancer Institute, 2013). Some side effects of this treatment 
are sweating, loss of sex drive, anergia, osteopenia and possibly anemia (low red blood 
cell count)(National Cancer Institute, 2013, CCS, 2010). 
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2.2 Wait Times 
2.2.1 Definition of Wait Time 
Waiting time refers to the length of time required for a patient to receive a desired 
service. Wait times can affect a patient's ability to benefit from certain health services by 
delaying their access to those services (Macdonald et al. , 1998). 
At this time, there are no nationally standardized definitions for wait times; 
specifically, when a wait begins and when a wait ends, nor are there are standards for 
measuring those waits (e.g. mean, median, 901h percentile). For instance, some studies 
reporting wait times in Canada may investigate the time elapsed from decision to treat to 
first treatment, diagnosis to first treatment, date of booking hospital appointment to first 
treatment, or biopsy to first treatment. Moreover, provinces are only reporting on data for 
a small number of health services. Most importantly, these reports on wait times only 
reflect a fraction of the total wait time a patient may experience throughout the care 
pathway (Canadian Partnership Against Cancer, 2012). To this extent, understanding and 
comparing wait times in the literature, and between provinces remains difficult. 
Under the aegis of the Western Canada Waitlist Project (WCWL), Sanmartin 
(200 I) recommends specific definitions for studying and reporting on wait times. First, 
the wait time to see a family physician should begin with first contact with that provider 
and ends with the first visit. The wait time to see a specialist begins with date of referral 
and ends with the first visit. Diagnostic tests can confirm diagnoses and treatment 
decisions. The waiting time for diagnostic testing is defined as the time between the date 
of the request for a specific test and the date of examination. Lastly, patients can wait for 
further treatments or consultations, beginning upon referral to other specialists or 
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decision to treat. This study employs these definitions for collecting and reporting data 
about wait times for prostate cancer treatment. 
2.2.2 Factors Contributing to Wait Times 
2.2.2.1 Health Care Systems Management 
A waiting list is a roster of patients waiting for a particular health service 
(Macdonald et al., 1998). According to the Romanow Report (2002), physicians or 
hospitals manage wait lists for specific services individually, making it very difficult to 
track and monitor these lists. There is very little collaboration and coordination that takes 
place between physicians or hospitals. Each specialist's list may vary in size, which can 
change how long patients may experience a wait. A patient on one physician's list may 
wait longer for a service than a patient on another physician 's list for the same service 
(Macdonald et al., 1998). Lack of management can be considered one of the greatest 
factors impacting wait lists (Romanow, 2002). 
2.2.2.2 Aging Populations 
Some wait lists, particularly for age sensitive conditions, are increased due to the 
aging population. Macdonald et al. (1998) believe this is cause for concern because older 
age populations consume more health care services than other populations, particularly 
for a variety of medical services such as radiation oncology, which is already under 
pressure. 
2.2.2.3 Patterns ofDisease 
The waiting times for individuals may also be affected by the increased rates of 
illness and disease throughout the province. According to the Department of Health and 
Wellness of Nova Scotia (2009), chronic conditions such as diabetes, heart disease, and 
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arthritis are costing Nova Scotia taxpayers an estimated $3 billion a year. Increased 
incidence and prevalence stimulate demand for health services and contribute to wait 
times in any province. Furthennore, since the development of new detection methods 
and a push for earlier detection of disease, there has been a substantial increase in new 
cases of cancer and other diseases, further increasing demand for health services. This 
has put substantial pressure on disease specific services such as radiation oncology 
(Macdonald et al., 1998). For example, the PSA test may reduce the rate of death from 
prostate cancer by 20%, but it may be associated with a high risk of over diagnosis 
thereby increasing demand for health services (Schroder et al. , 2009). 
2.2.2.4 New Technology 
Physicians today use many types of diagnostic imaging tests to confirm a clinical 
diagnosis like a magnetic resonance imaging (MRI) or a computer tomography (CT) 
scan. These tests make up three and 11% of our health care systems imaging technology 
costs respectively (CIHI, 2006). Due to increased demand for these tests, patients still 
seem to be reporting difficulties accessing these services. Similarly, patients who require 
diagnostic imaging for cancer diagnosis may experience the same waits associated with 
these diagnostic-imaging technologies (CIHI, 2006). 
2.2.2.5 Age 
A patient's age can influence how he is managed for prostate cancer care. 
According to Dr. Chris French (personal communication, April, 2010) radical treatment 
is rarely offered to patients with a life expectancy ofless than 10 years. This is because 
the mortality due to prostate cancer is not necessarily reduced and sometimes the 
treatment itself can cause harm. Also due to the nature of the triage method Bott, Periera, 
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Eddy, and Montgomery (2006) suggest that it might be more suitable to manage patients 
older than 80 years without biopsy. We suspect that older men may wait longer to see a 
urologist given these local practices in St. John's, NL (Dr. Chris French, urologist, 
personal communication, May, 201 0). A study by Fleshner et a!. (2000) illustrated the 
differences in practices between Canadian and American urologists in this regard. 
Urologists in Canada were less likely to perform regular biopsies and aggressive 
treatments for men over the age of 70 years than urologists located in the United States. 
2.2.2.6 Community of Residence 
According to Campbell, Ritchie, Cassidy, & Little (1999), there are many benefits 
with the centralization of resources such as cancer care in a health system, but there is 
also a glaring weakness. Patients from remote areas seeking cancer care treatment or to 
see a specialist can experience a sizeable difference in accessibility of health services 
compared to those patients living in urban areas (Campbell eta!., 1999). 
Cancer patients' treatment time may depend on their area of residence (Launoy, 
Le Coutour, Gignoux, Pottier, and Dugleux, 1992). Launoy et a!. ( 1992) studied how 
community of residence impacts the utilization ofhealth care services for colorectal 
cancer. Specifically, their study compared males and females in rural and urban areas 
and their clinical symptoms, treatment center (specialized or non-specialized), and 
survival for colorectal cancer. They found that people living in rural areas were less 
often treated in specialized centers (41-45% ofmales and 32-35% of females) than urban 
patients (50-55% ofmales and 51-57% of females). Moreover, severe clinical symptoms 
were significantly associated with rural women (p <0.05) more than urban women, but no 
difference in survival was illustrated. The authors attributed the severe clinical symptoms 
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found in women to longer waiting times for health services. However, no analysis of 
waiting times was presented in the journal article to support those claims. 
2.2.2.7 Stage of Cancer 
In a study by Mayo et al. (200 1 ), the median waiting times were shorter for patients 
with more advanced stage of cancer than those with more localized cancer. This can be 
attributed to providers triaging patients with early stage diagnosis to wait longer than 
patients with an advanced stage of cancer. A later study by Comber, Cronin, Deady, 
Lorcain & Riordan (2005) suggests that patients with early stage of cancer are 
experiencing longer waits than those with late stage diagnoses. It seems that "patients 
with longer waiting times generally had less advanced disease and better survival, 
suggesting that typical delays are not of clinical significance, but that patients with 
advanced disease are probably being "fast-tracked" by GPs and hospitals" (Comber et al., 
2005, pg. 1). 
2.2.3 Benchmarks for Wait Times 
The Western Canada Wait List Project (WCWL) was created in 1998 through the 
funding of Health Canada's Health Transition Fund. The WCWL was created with the 
objective "to improve the fairness of the system, so that Canadians' access to appropriate 
and effective medical services is prioritized on the basis of need and potential to benefit." 
(Western Canada Wait List Project [WCWL], 2005, pg. 1). In 2004, Canada's First 
Ministers created a strategy to improve wait times called Canada's 10-Year Plan to 
Strengthen Health Care. This 1 0-year plan focused on ensuring that Canadians have 
access to care they need, when they need it. According to the plan (2004), each province 
or territory will help in providing benchmarks (a maximum wait time that is 
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recommended by experts to be medically acceptable) by the end of2005. To this end, 
every province will aim to meet the objective of timely care. In addition, the report 
called upon each province and territory to report their current wait times for the five 
priority areas of health (cancer, diagnostic imaging, joint replacements, heart, and 
cataract surgery) to their citizens. 
In 2005, Ontario's Ministry of Health and Long-Term Care (MHLTC) issued an 
announcement on the benchmarks for the five priority areas outlined above2. Under these 
new benchmarks, provinces and territories aimed to provide and report on wait times in 
reference to those standards. Among others, the cancer benchmark was established as 
four weeks from when the patient is ready to receive treatment to the actual date of 
radiotherapy. 
The Wait Time Alliance (WTA) was created as a physician' s response to 
Canadians' concerns about health care services. The Canadian Medical Association 
(CMA) and other specialty associations concerned with wait times represent the WTA. 
The WT A issued a report in 2005 - It's About Time - describing their recommendations 
for medically acceptable benchmarks. Their recommendations are illustrated along with 
the federal government's benchmarks in Table 2.2. Although the WT A released their 
suggestions for benchmarks, each province and territory continue to report on the wait 
times established by Ontario's Ministry of Health and Long-Term Care (MHLTC). 
2 FPT Announcement, December 12, 2005 
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Table 2.2: Canadian Established Benchmarks (MHLTC, 2005) 
Treatment Provincial Benchmarks Wait Times Alliance Benchmark 
Radiotherapy for cancer Radiation therapy to treat cancer within 4 weeks of A) Consultation within I 0 working 
patients being ready to treat days 
B) Treatment within 10 working days 
of consultation 
Hip/knee replacement Hip and knee replacements within 26 weeks (6 months) A) Consultation within 3 months 
B) Treatment within 6 months of 
consultation 
Cardiac Cardiac bypass surgery A) Level I patients within 2 weeks; 
B) Level II patients within 6 weeks; 
and 
c) Level III patients within 26 weeks 
Cataract surgery Surgery to remove cataracts within 16 weeks for Within 16 weeks (4 months) of 
patients who are at high risk consultation 
Diagnostic imaging None given, although screening guidelines for breast A) Cardiac nuclear imaging within 14 
and cervical cancer were proposed days 
B) Other imaging within 30 days 
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2.2.4 Recommended Wait Times For Cancer Treatment 
Wait times for cancer treatment in Canada remain a major problem in the delivery 
of care. Different interest groups and researchers have provided many different 
recommendations for medically acceptable wait times based on the available evidence 
and expert opinions. Table 2.3 summarizes these recommendations. 
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Table 2.3: Recommended Wait Times for Cancer Treatment From the Literature 
Reference Wait Time Definition Recommended Maximum Type of Cancer Type of Treatment 
Wait Time 
UK National Health GP referral to specialist 2 weeks All cancer All surgeries 
Service, 2006 assessment 
UK National Health Diagnosis to treatment I Month All cancer All surgeries 
Service, 2006 
UK National Health Urgent GP referral to treatment 2 Months All cancer All surgeries 
Service, 2006 
Canadian Society of Referral to consultation 2 weeks All cancer All surgeries 
Surgical Oncology, 2012 
Canadian Society of Conclusions of preoperative 2 weeks All cancer All surgeries 
Surgical Oncology, 20 12 tests to treatment 
Ontario's Ministry of Radiation therapy: ready to treat 4 weeks All cancer Radiotherapy 
Health and Long-Term to treatment 
Care (MHLTC), 2005 
Canadian Surgical Wait Decision to operate until day of J."High Risk !Q8d Prostate cancer Prostate cancer surgery 
Times (SWAT) Initiative, surgery 2.bMedium Risk ~60d 
2006 3.cLow Risk- ~90d 
Moul et al., 2004d From diagnosis to treatment 3 months Prostate cancer Radical prostatectomy 
Esmail and Walker, 2005 From diagnosis to treatment 4 weeks (range: 3 to 6 weeks) Prostate cancer Radical prostatectomy 
• High risk individuals are categorized with PSA > 20 ng/ml or Gleason score > 7 or ;::: T2 
b Medium risk individuals are categorized with PSA > I 0 - 20 ng/ml 
c Low risk individuals are categorized with PSA < I 0 ng/ml or Gleason score < 7 or ;:::T 1- T2a 
d Moul et al. (2004) study only reported in abstract form. Specifics were taken from Saad et al (2006) 
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The Canadian Society of Surgical Oncology (CSSO) and the United Kingdom 
National Health Service (UKNHS) made public their position statements on what they 
believe the maximum wait time for cancer surgeries should be. The CSSO states: 
There is evidence that the number of patients requiring surgery for their diagnosis 
and/or management of various cancers is increasing. Although there are many 
factors involved in the timely delivery of excellent health care, the Canadian 
Society of Surgical Oncology recommends that appropriate numbers of specialists 
be suitably trained and have available the necessary resources to allow patients to 
be seen in consultation within two weeks of referral and to allow treatment, 
including surgery, to be initiated within two weeks of completion of any 
necessary preoperative tests. (CSSO, 2012) 
The United Kingdom National Health Service created a waiting times assignment 
that began in 1998 under the aegis of the National Cancer Director Michael Richards who 
said, "A long-term goal set in the NHS Cancer Plan was that no suspected cancer patient 
should have to wait more than a month from the time of being referred by their GP, until 
the start of treatment" (Savage, 2007, pg. 3). From this, the UKNHS stated that there 
would be a maximum wait of two weeks from the time of general practitioner's (GP) 
referral to the time for a specialists' evaluation, a maximum one-month wait between 
diagnosis and treatment, and a two-month wait between an urgent GP referral and actual 
treatment (Savage, 2007). 
2.2.5 Current Reported Prostate Cancer Wait Times 
Fifteen studies reporting wait times for prostate cancer were identified through the 
literature search. There were many differences among these studies such as: (a) study 
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designs; (b) analyses; and (c) wait time definitions. Because of the different wait time 
definitions, the reporting of wait times varied across all intervals. The definitions used by 
each study typically reflected their study designs and data that were available. These 
studies are summarized in Table 2.4. 
Through retrospective chart auditing, Kavanagh, Lee, and Donnelly (2008) 
described wait intervals for prostate cancer care patients may experience from the time of 
general practitioner referral to the date of decision for first treatment. This study also 
examined wait times for each individual treatment modality. No other study in Canada 
has been able to describe all of these intervals of wait. Results showed a median wait of 
seven days from date of referral to first visit, 19 days from decision to biopsy to date of 
biopsy, 22 days from date of biopsy to date of diagnosis, and 52 days from date of 
decision for treatment to first treatment date (by treatment type). Overall, patients 
experienced a median overall wait of 101 days (90th percentile- 187.2 days) from date of 
referral to first treatment (all treatment types) and an overall median wait of 52 days from 
diagnosis to first treatment (90th percentile - 146.2 days). Additionally, patients who 
opted for curative radiation experienced a median wait of 145 days (90th percentile-
222.8 days). These results clearly exceed the CSSO's and the OMHLTC' s 
recommendations for acceptable wait times. 
A population-based study of the waiting times for prostatectomy in Ontario by 
Siemens, Schulze, Mackillop, Brundage, and Groome (2005) linked the Ontario Cancer 
Registry data to hospital discharge data to follow men between 1980 and 2000 who were 
treated with radical prostatectomy in Ontario. Between 1980 and 2000 there were 9,524 
men who were treated with radical prostatectomy. During this period, the percentage of 
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men who were treated surgically for prostate cancer increased from three to 20%. Most 
importantly, the overall time from diagnosis to surgery for radical prostatectomy had 
almost doubled, with an increase in a median waiting time from 55 to 95 days between 
1996-2000. Hospitals in Ontario showed an increase in surgical volumes associated with 
significantly higher waiting times (up to 20 days longer in 1996-2000 (p <0.001 ). 
Simunovic et al., (2005) reported a non-significant increase for surgical waiting times for 
prostate cancer between 1993 and 2000 of 4% (80 days to 83 days). Although the 
comparison between waiting times was not significant, the reported 75th percentile was 
120 days, which still suggests that wait times in Ontario during the study period clearly 
exceeded the CSSO's and the federal government's benchmark recommendation for 
acceptable wait times (see Table 2.3). 
Research studies completed by Saad et al. , (2006) and Kavanagh et al. , (2008) 
have been suggesting that prostate cancer wait times in Canada are increasing. Recently, 
CIHI (20 12) released a report stating that provinces are continuing to struggle to reduce 
wait times. NL demonstrated a lower than national average for radiation therapy, knee 
replacement, and cataract surgery. 
In contrast, countries like the United States and the United Kingdom have 
demonstrated prostate cancer wait times that are comparable, but their wait time trends 
seem to be declining. The United States and Canadian practice experiences and clinical 
volumes are not significantly different however (Fleshner et al. , 2000). 
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Table 2 4 · Wait Times Studies for Prostate Cancer 
Reference Country Number of Patients (n) Wait Time Definition Median (days) 
Stevensetal., 2010 Canada 41 Suspicion to Urologist 40 
Suspicion to Diagnosis 53 
Suspicion to Radical Radiotherapy 241 
Kavanagh et a!., 2008 Canada 997 Referral to clinic 7.0 
Referral to biopsy 21.0 
Referral to diagnosis 43 .0 
Referral to treatment 101.0 
(all modalities) 
Simunovic eta!. , 2005 Canada 798 Surgeon consult to hospital admission 80 in 1993 
83 in 2000 
Simunovic eta!. , 2001 Canada 58 Referral to surgery 64in 200 1 
Siemens eta!., 2005 Canada 9524 Diagnosis to hospital admission 55 in 1980-85 
95 in 1996-2000 
Esmail and Walker, 2005 Canada Not Available Diagnosis to prostatectomy 42 (24.5-56) 
Cancer Care Ontario, 20043 Canada 51 Referral to operation 65 
66 Consult to operation 59 
Nam eta!. , 2003 Canada 645 Diagnosis to surgery 68 
Mouletal. , 2004b USA 3324 Diagnosis to surgery 119 in 1990 
63 in 2002 
Boorjian eta!. , 2005 USA 3149 Biopsy to surgery 69 
Lee et a!. , 2006 USA 169 Biopsy to surgery 56 (14 to 378) 
Subramanian, Puranik, & United Kingdom 40 1. GP referral to surgery l. 244 
Mufti, 2003 2. Diagnosis to surgery 2. 76 
Spurgeon, Barwell, & Kerr, England 677 I. GP referral to urgent surgery l. 53 
2000 2. GP referral to non-urgent surgery 2. Ill 
Hurst & Siciliani, 2003c Spain Not Available Diagnosis to radical prostatectomy 1992 - 11 9.43 
2000 - 43 
Graefen eta!. , 2005 Germany 795 Diagnosis to surgery 54 
a Cancer Care Ontario study used a survey approach and this wait times included all urological cancer surgeries 
b Moul et a!. (2004) study was not found in full report, but in abstract form. Details from study were taken from Saad et a!. (2006) 
c This study used a questionnaire approach 
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2.2.6 Clinical Impact from Prostate Cancer Wait Times 
The effectiveness of prostate cancer treatment can be judged in part from survival 
statistics. Survival itself can be judged in a variety of ways. According to the literature, 
the best indicators of survival for prostate cancer are survival rates that measure: (a) 
biochemical recurrence free survival; (b) biochemical relapse free survival; (c) 
biochemical failure free survival; (d) biochemical-free recurrence; (e) biochemical 
progression free survival; (f) and biochemical disease-free survival. All of these rates 
refer to the PSA level in the blood, which upon surgical removal of the prostate should be 
untraceable. Six studies were found comparing wait times to biological outcomes 
(Prostate-Cancer, 2011). These studies can be found in Table 2.5. 
In an abstract published in 2004 from the American Urological Association 
annual conference, Moul et al. suggested that high-risk patients who wait greater than 3 
months between diagnosis and surgery are 1.19 times more likely to have recurrence of 
their cancer (1.19, p=0.044) than high-risk patients who waited less than three months. 
Though widely cited, it is imperative to mention that, to our best knowledge, outside of 
the abstract form this study has not been published and therefore has not been peer-
reviewed. Saad et al. (2006) remains the only study (that we know of) that has published 
the actual research data findings from Moul et al. (2004) by contacting the author 
personally. 
A study by Nam et al. (2003) casts doubt on the safety of delay beyond three 
months in achieving long-term cancer control. In a population-based retrospective chart 
review, these researchers observed 645 men who had radical prostatectomy surgery 
between 1987 and 1997. They showed that men who had surgery within 90 days of 
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diagnosis experienced a statistically significantly higher 1 0-year biochemical recurrence 
free survival than those who had surgery 90 days or longer after diagnosis (74.6% vs. 
61.3%, p = 0.05). 
In contrast, a study by Khan et al. (2004) found that wait times of up to five 
months do not negatively impact PSA recurrence free survival at 10 years follow-up (p-
value >0.05). In fact, patients who had surgery longer than 150 days from diagnosis had 
superior long-term cancer control rates. Furthermore, this study analyzed men considered 
high-risk and found no adverse outcome. This analysis only included 55 patients, so no 
data were shown in the article for lack of statistical power. There are two possible 
confounders that may explain why these results may have occurred between the Nam et 
al. (2003) and Khan et al. (2004) studies: 
I. The Nam et al. (2003) study had considerably more men in the delayed 
group with a PSA greater than 10 ng/mL than Khan et al. (2004), which 
may have added to the likelihood of biochemical failure. 
2. The Khan et al. (2004) study had a possible selection bias as men with 
lower Gleason and PSA score along with normal DRE findings 
experienced the greater delays. 
Considering these studies, the consensus on whether or not men with longer wait 
times will face significantly worse survival rates is still unknown (Khan et al. , 2004; 
Graefen et al., 2005; Boorjian, Bianco, Scardino, and Eastham, 2005; Lee, Allareddy, 
O'donnell, Williams, and Konety, (2006). 
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Table 2.5: Wait Time and Risk of Cancer Recurrence 
Author No. of Patients Years Key Groups Key Outcome: PSA recurrence 
Nam eta!., 2003 645 1987-97 Wait ~versus <3 months Adjusted HR = 1.46; P=0.05 
Moul eta!. , 2004" 3324 1988-2002 Wait ~ versus <3 months Adjusted HR = 1.19; P = 0.044 
Khan eta!. , 2004 926 1989-1994 Wait Groups P-value at 5 year survival P-value at 10 year survival 
~60d >0.05 >0.05 
61d to 90d >0.05 >0.05 
9 1d to 120d >0.05 >0.05 
121d to 150d >0.05 >0.05 
> 150d >0.05 >0.05 
Graefen eta!. , 2005 795 1992-2000 Time to treatment as Adjusted HR = 1.0; P = 0.84 
continuous variable 
Boorjian eta!. , 2005 3149 1987-2002 Wait ~versus <3 months Adjusted HR = 1.0 1; P = 0.939 
Lee eta!., 2006 169 2001-2004 Time to treatment as Adjusted HR = 0.994; P = 0.62 
continuous variable 
PSA = prostate specific antigen, HR = hazard ratio 
"Moul eta!. (2004) study only reported in abstract form. 
Details of study were taken from Saad et al study in 2006. 
All studies used retrospective cohort design 
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2.2.7 The Wait Time Model for Men Seeking Prostate Cancer Care in NL 
Men journey through the prostate cancer care pathway through several steps, each 
of which involves a certain amount of waiting time. Figure 2.2 illustrates steps most 
commonly experienced by men seeking prostate cancer care in NL. 
The first step begins with the patient's GP making a referral to the urologist and 
extends until the patient has the first visit with the urologist. Next, the patient and the 
urologist decide on the date ofbiopsy and time elapses until the biopsy is performed. 
After the biopsy, there is a waiting period until the urologist receives the biopsy report 
and then informs the patient ofthe results of the biopsy. Lastly, those men who have been 
diagnosed with cancer decide on a treatment and wait until their treatment is arranged and 
commences. Additional waiting time intervals were measured: (1) total waiting time from 
the GP referral to when the urologist informed the patient of their results; and (2) waiting 
time from GP referral to the urologist until date of first treatment. 
Prostate Cancer Care Pathway for Men in NL 
GP Referral to First Visit wim 
Urologist 
Decis;on to Biopsy to Date of 
BlO s 
Date of Biopsy to Receipt of 
Pathology Report 
Receipt of Pathology Report to 
Date Informed of Results 
DeciSIOn to Treat to Date of Ftrst 
Treatment 
GP Referral to Date Informed of 
Results 
GP Referral to Date of First 
Treatment 
Figure 2.2: The Prostate Cancer Care Pathway 
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To our knowledge, there are only three Canadian studies that examined the entire 
urological cancer care pathway (Kavanagh et al., 2008; Cole, Hopman, & Kawakami, 
2011) and only two for prostate cancer (Stevens et al., 201 0; Kavanagh et al. , 2008). This 
study will examine all of the intervals that men experience while seeking urological care 
for suspected or confirmed prostate cancer. 
2.2.8 Methodological Approaches to the Study of Waiting Time 
Wait times in Canada have been primarily examined through retrospective chart 
audit reviews and reviews of hospitalization data by various studies throughout Canada. 
(Cole, Hopman, & Kawakami, 2011; Kavanagh et al. , 2008; Simunovic et al. , 2005; Nam 
RK et al., 2003; Simunovic et al. , 2001). These designs have limitations: retrospective 
chart reviews and hospitalization data may rely on accuracy of the clinical records, and 
important data may not be available because it may not have been inputted into the 
system to begin with. However, a retrospective chart review study design is very feasible, 
accessible, and allows for a study to be completed in a practical amount of time. 
To date, there have been few studies that have examined wait times for prostate 
cancer care in Canada and in NL. The purpose of this study is to measure all the wait 
times for prostate cancer patients between when a patient is referred by their family 
physician until they receive their first treatment. This study implemented a retrospective 
chart review similar to other Canadian studies. A retrospective chart review was used as 
the study design because of the wide availability of patients' charts and electronic 
medical records, feasibility and the ability to capture the desired wait intervals. 
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2.3 Summary 
The literature review suggests that prostate cancer care wait times in Canada are 
increasing. Provincial benchmarks provided by Ontario's Ministry of Health and Long-
Term Care in 2005 provided provinces with a platform to begin reporting the wait time 
data to the public. However, these provincial benchmarks lacked specific criteria for 
prostate cancer. This study will use a local urologist practicing in St. John's, NL to 
provide benchmarks on prostate cancer care. There is little consensus in the literature on 
benchmarks for prostate cancer care. Moreover, limited research exists documenting how 
long patients are waiting for prostate cancer care in Newfoundland and Labrador. 
Using a retrospective chart audit review, this study will focus on the wait times of 
men who are referred to one of the practicing urologists in St. John' s, NL at the Health 
Science Centre. We will be able to review the charts ofurology patients who have 
received a prostate biopsy and/or TRUS at the Health Science Centre between April 1, 
2009 and March 31 , 2010. In each chart we will be able to identify important patient 
demographic characteristics and key dates such as: (a) the date of referral to a urologist, 
(b) the date first seen by the urologist, the date of the biopsy, (c) date the physician 
receives the biopsy results, (d) the date the patient is informed of the biopsy results, (e) 
the date the patient and provider decides on a treatment date, and (f) the date of the first 
treatment. 
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3.1 Study Design 
CHAPTER3 
METHODS 
This study used a retrospective chart review of prostate cancer patients in St. 
John's, NL over a period of 12 months between April 1, 2009 and March 31,2010. All 
of the urologists (6) in St. John's, NL at the Health Science Centre agreed to participate 
in the study. 
3.2 Sample 
Electronic and paper charts of patients who had been referred to one of the six 
urologists in St. John's, NL at the Health Science Centre and received a biopsy and/or 
TRUS between April I, 2009 and March 31, 2010 for suspected malignancy were audited 
for this study. Sample size and power analysis can be found in Chapter 4 section 4.1. 
3.2.1 Eligibility 
To be eligible for the chart review, patients must have resided in NL and had their 
first biopsy/TRUS from one of the urologists participating in the study between April 1, 
2009 and March 31 , 201 0. Patients whose charts were not available, who were younger 
than 19 years of age, or had been previously diagnosed with any other type of cancer 
were excluded. Furthermore, patients were also excluded if their eligibility criteria could 
not be determined. 
3.3 Data Collection 
Charts of prostate cancer patients seeing any of the six urologists in St. John's 
were reviewed to gather data on patient wait times. The data collection took place in the 
Health Science Centre in St. John's, NL. Each chart was reviewed using the chart audit 
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tool presented in Appendix A. First, all electronic charts were audited using a computer 
located in the department of Community Health and Humanities in the Health Science 
Centre, St. John's, NL that had the Meditech system installed. Meditech is an online 
patient care system that health care providers use to manage their patients' care. Medical 
records personnel were asked to identify all patients who had a prostate biopsy/TRUS 
between April 1, 2009 and March 31, 2010. MCP numbers were recorded once Medical 
Records identified all patients who had a biopsy/TRUS. Using these MCP numbers, 
medical records pulled the paper charts on all eligible patients for the study. The paper 
charts were used to fill in any missing data not found in the Meditech system (e.g. GP 
letter of referral). No identifiable patient information was entered during the data 
entering process, and all MCP numbers were recorded on the chart audit forms. Auditing 
of the paper charts took place in a private area located in a private research office in the 
medical records department. 
Data were collected on patient characteristics (age and community of residence), 
clinical characteristics (PSA score upon referral, Gleason score, prostate volume and 
clinical stage of cancer) and key dates (general practitioner referral to first visit with 
urologist, biopsy, pathology report, when patient was informed of results, and first 
treatment). Data were also collected on whether there were any delays in patient care and 
the reason for that delay. Although each patient was given a study identification number, 
MCP numbers were only recorded on the chart audit form. MCP numbers were used 
only to identify charts (in case they were not immediately available for review) or tore-
call a chart in case of an error in data entry. 
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3.4 Analysis 
A database was created using SPSS data entry software. To clean the data, 
frequencies on all variables were run to identify incorrect, implausible, or missing data. 
3.4.1 Variables 
The main outcome (dependent) variables were seven wait intervals: (a) general 
practitioner referral to first visit with the urologist; (b) the decision to biopsy to biopsy 
date; (c) the biopsy date to the date the pathology report was received; (d) date pathology 
report received to the date of notification of the patient; (e) decision to treat to first 
treatment (if cancer); (f) GP referral to notification of results; and (g) GP referral to first 
treatment (cancer patients only). Each dependant variable was coded as either meeting 
the benchmark (0) or not meeting the benchmark (1). Appendix B shows each of the 
dependent variables, and how they were coded. 
There were no established Canadian benchmarks for these intervals; so a local 
urologist was asked to identify acceptable wait times for each interval. Specifically, he 
was asked "if your father was seeking care for prostate cancer-like symptoms, how long 
would you want him to wait from the time he was referred to a urologist to seeing the 
urologist, from the decision to biopsy to biopsy date, from the biopsy date to the date the 
pathology report received, from pathology report received to the notification of the 
patient, from decision to treat to first treatment? The two dependant variables, from 
referral to notification and referral to treatment were determined by adding each of the 
benchmarks together. These benchmarks can be found in Table 3.1. 
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Table 3.1: Local Benchmarks Established by Local Expert Opinion 
Interval Benchmark 
"GP referral to first visit with the specialist :::;60 days 
Decision to biopsy to date of biopsy :::;14 days 
Biopsy to receipt of the pathology report :s;ll days 
Receipt of the pathology report to patient informed of their results :::;7 days 
Decides to treat to first treatment * ~4 days 
"GP referral until notification of results :s;J 02 days 
3GP referral until first treatment* ~ 16 days 
"GP - General Practitioner 
*Includes individuals with prostate cancer only 
In the analyses, we were particularly interested in differences in wait times related 
to: (a) age; (b) community of residence; and (c) urgency. According to local expert 
opinion, patients can be managed differently according to their age (personal 
communication, Dr. Chris French, May 25, 2009). Patients who were less than 70 years 
old on date of first visit with the urologist were coded as young (0) and patients with age 
older or equal to 70 were coded as old (1 ). Community of residence was coded as urban 
( ;::i 0 000) (0) and rural (< I 0 000) ( 1 ). This definition has been used in other NL studies 
(Mathews & Edwards, 2004; Mathews, Rourke, and Park, 2008). 
We were also interested in describing men who would be considered urgent and 
non-urgent, based on patients ' clinical characteristics from as early on in the care-seeking 
process as possible. There was no single urgency variable available that would capture 
urgency and include all men throughout all of the wait intervals. Therefore, nine 
variables were considered to capture urgency: (a) age; (b) referral reason; (c) PSA on 
referral; (d) ORE; (e) prostate volume; (f) having cancer; (g) Gleason; (h) clinical risk; (i) 
and stage of cancer. Table 3.2 presents each variable that could be used in each interval. 
Two of the variables, prostate volume and referral reason, were of limited use in the 
analyses because of a large amount of missing data and minimal variation, respectively. 
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Following the SWAT's guidelines (2006), patients who had a PSA less than 10 
nglmL, Gleason scores less than seven, and a clinical stage of cancer ofT 1-T2a were 
coded as early-stage (0). Patients who had a PSA greater than 10 nglmL, Gleason scores 
greater than seven, and a clinical stage of cancer greater than or equal to T2 were coded 
as late-stage (1). When PSA differed from clinical stage, Gleason score was used to 
determine the category of the patient. 
Other variables that were considered in the analysis were having prostate cancer 
(have cancer or no cancer), delay during any of the wait intervals, and comorbidities: (a) 
diabetes; (b) cardiovascular disease; (c) musculoskeletal disease; (d) neurological disease; 
(e) gastrointestinal/herniation; (g) hypertension; and (h) other (cataracts and chronic 
obstructive pulmonary disease [COPD]). Patients with comorbidities were coded as 
having comorbidities (1) or not having any comorbidities (0). Men with prostate cancer 
were coded as having cancer (1) or not having prostate cancer (0). 
Three types of delays were captured: (a) patient (0), defined as a delay related to 
men not seeking medical attention in the presence of their prostate cancer symptoms (e.g. 
canceling an appointment, vacationing, sick, seeking second opinion, etc.); (b) physician 
(1 ), defined as a delay related to the urologist affecting the attainment of a consultation, 
biopsy, or surgery (vacation or sick); and (c) system (2), defined as a delay related to 
health care system delivery issues such as a delay in appropriate diagnostic assessment 
initiated by a physician or referral in the presence of prostate cancer symptoms. For 
example, if there were a loss of referral letters, biopsy reports not available, or lost 
appointment at any stage in the patient care pathway indicating in the patients' charts. 
Men not experiencing a delay were coded as no delay (3). The season when patients 
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were first referred to the urologists was also collected. Appendix C describes how the 
covariate and independent variables were coded for the statistical analysis. 
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Table 3 2· Variables Used to Detennine the Urgency of Men at Each ofthe Wait Intervals 
Referral to first Decision to Biopsy to date Date pathology Decision to Referral to Variable report received Referral to first 
visit with biopsy to date pathology to notification treat to first notification of treatment" 
urologist of biopsy report received 
of results treatment" results 
Age X X X X X X X 
Referral 
Reason* X X X X X X X 
Has Prostate 
Cancer" X X X X 
Prostate 
Volume** X X X X X 
DRE X X X X X X 
PSA X X X X X X X 
Gleason" X X 
Clinical Risk" X X 
Stage" X X 
a DRE - Digital Rectal Examination 
b PSA- Prostate Specific Antigen 
*Not considered because little variation exists between referral reasons (PSA/DRE/Family History and Urinary problems) 
**Not considered because there is a large amount of missing data. 
" Only includes men with prostate cancer 
42 
3.4.2 Statistical Analyses 
Statistical analysis was performed using SPSS 18.0 to address each study 
objective, as described below: 
Objective #I: to use chart audit data to measure the wait time intervals for patients 
with suspected or confirmed prostate cancer in NL. Specific intervals of wait time will 
be described, including those related to elapsed between: (a) general practitioner (GP) 
referral to first visit with an urologist; (b) decision to biopsy to date ofbiopsy; (c) date of 
biopsy to when the pathology report is received by the urologist; (d) date pathology 
report received to when the patient is informed; and (e) decision to treat to date of first 
treatment. 
This study used frequencies to describe the characteristics of the sample. In 
addition to providing the frequency and proportion of patients who met and did not meet 
the benchmarks for each interval, medians, means, ranges, and standard deviations for 
each wait period were reported to highlight the distribution for each interval. The 90th 
percentile of each wait interval was also reported. The 90th percentile corresponds to the 
statistic that is reported by the province and allows the comparison of data collected in 
this study to the data collected by the province. 
Objective #2: to examine differences in wait times related to community of 
residence, urgency, and age, including differences in wait times for men who: (a) met and 
did not meet locally established benchmarks, (b) men from urban and rural communities, 
(c) men with non-urgent and urgent symptoms; and (d) young (less than 70 years) and old 
(70 years and older) men. 
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Chi-square tests were used to examine the relationships between all seven wait time 
benchmarks and the three key areas of interest: (a) community of residence, (b) urgency, 
and (c) age of men with suspected of confirmed prostate cancer. Specifically, tests were 
conducted to determine if there were significant differences between men who did or did 
not meet the benchmark with respect to the following characteristics: community of 
residence (urban versus rural); urgency (urgent and non-urgent); and age (young and old). 
To adjust for potential confounders, multiple logistic regression was used to 
identify any significant (p <0.05) predictors (independent and control) in whether or not 
men met or did not meet each individual benchmark. Potential predictors for each 
regressional model were selected based on significant chi-square analyses. Any variables 
that were built on one another only had one variable entered into the model (e.g. Gleason, 
clinical risk, and stage of cancer). If a significant Chi-square result was found, Gleason 
score was used in lieu of clinical risk or stage of cancer as most urologists consider the 
Gleason grade as the most powerful preoperative prognostic value (So & Goldenberg, 
2004). There were no large standard error values (indicating multicollinearity), found 
during the multiple logistic regression analyses. Supplementary analyses were conducted 
to test the main effects for interactions to include in the regression model (Appendix D & 
E). 
3.5 Chart Audit Ethical Considerations 
Memorial University's Human Investigation's Committee (HIC) approved this 
study (Appendix F). Approval from Eastern Health' s Research Protocol Approval 
Committee (RP AC) was also obtained (Appendix G). 
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MCP numbers were kept on the chart audit form and not entered during the data 
entering process. Numbers were only used to re-retrieve any charts in case of missing 
data or data entering error. Names or other personal identifiers were not recorded or used 
in this study. 
All data were stored in locked filing cabinets and on password protected 
computers in the Division of Community Health and Humanities, Memorial University of 
Newfoundland. The thesis supervisor and the researcher had access to the filing cabinet 
or the password-protected computer. 
3.6 Limitations 
Chart auditing in this study attempts to determine all intervals of wait a patient 
may experience while seeking health services for prostate cancer. However, audits of 
urology charts do not provide data on patient waits between first contact with the general 
practitioner for an appointment and first visit with the general practitioner. In addition, 
the auditing of urologists' charts will not capture wait times that a patient may experience 
while seeing an oncologist, nor will it capture the interval between requesting a GP 
appointment to first appointment with the GP. This study will only capture the waits for 
visits and treatments provided or coordinated by a urologist. 
3.7 Knowledge Transfer 
This study was developed in collaboration with the researcher' s supervisory 
committee, urologists, and prostate cancer support groups. The results of this project are 
relevant to cancer providers (urologists), the Departments of Health and Community 
Services ofNewfoundland and Labrador, and cancer advocacy groups (prostate cancer 
support groups), and the Canadian Cancer Society. Research findings will be presented 
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at Urology Rounds at the Health Science Centre in St. John's, NL. Summary reports will 
be provided to non-clinician stakeholders. Articles for peer-reviewed publication will be 
prepared and presentations made at seminars and national conferences. Meetings with 
key stakeholders will be held upon request. 
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CHAPTER4 
ANALYSIS 
4.1 Sample 
Between April 1, 2009 and March 31, 2010, 629 men who had been referred to a 
urologist practicing in St. John's, NL had a biopsy/TRUS for suspected or confirmed 
prostate cancer at the Health Science Centre in St. John's, NL. Among these, 29 (4.6%) 
individuals had more than one biopsy, leaving a total of 605 unique individuals. From 
this potential sample, 264 (43.6%) individuals were excluded from the study, leaving a 
final sample of341 (56.4%) eligible men. Figure 4.1 outlines the number ofmen 
excluded from the study and the reason they were excluded. 
List of Biopsy/TRUS Between April 1, 2009-
March 31 , 2010, n=605 
~----------~.~----------~ 
Had biopsy/TRUS before April 1, 2009, n=204 
• Had previous cancer, n=46 
Had biopsy/TRUS outside province, n=? 
.-----------~~~" ----------~ 
Non-residents of NL, n=3 
~-----------.~~--------~ 
Unable to confirm eligibility, n=3 
~----------~'~' ----------~ Died after biopsy, n= 1 
~---------------,-~~----------~ ~----------~~~" ----------~ 
Total individuals excluded, n=264 
.-----------~~~----------~ 
Total individuals included, n=341 
Figure 4.1 : Explanation For the Sample Size and Reasons for Excluded Individuals. 
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Given a sample size of 341, we were able to detect a 15% difference between urban 
( 49%) and rural patients (51%), and an 18% difference between old (18.5%) and young 
patients (81.5%) with an alpha of0.05 and a power of80%. We were also able to detect 
a minimum of 15.5% and a maximum 19.8% difference with an alpha of0.05 and a 
power of 80% between the variables "has prostate cancer" and "age" respectively. These 
calculations are based on the proportions found in Table 4.1 below. 
4.2 Characteristics of Sample 
4.2.1 Demographic and Clinical Characteristics 
Table 4.1 lists the patient demographic and clinical characteristics of the men who 
had a biopsy/TRUS between April 1, 2009 and March 31 , 20 I 0 at the Health Science 
Centre in St. John's, NL. Just over half of the men were from a rural area (51 %) and 
most men were young (81.5%). Ofthe 341 men in the study, 157 (46%) men had 
prostate cancer, and of those, over half (56%) were considered to be late-stage based on 
the stage variable. An abnormal DRE, elevated PSA, and/or a family history of cancer 
were the most common reasons for referring men to a urologist (98%). Over half(58%) 
of men referred for a biopsy/TRUS had cardiovascular disease. 
Three types of delays were captured: (a) patient, defined as a delay related to men 
not seeking medical attention in the presence of their prostate cancer symptoms (e.g. 
canceling an appointment, vacationing, sick, seeking second opinion, etc.); (b) physician, 
defined as a delay related to the urologist affecting the attainment of a consultation, 
biopsy, or surgery (vacation or sick); and (c) system, defined as a delay related to health 
care system delivery issues such as a delay in appropriate diagnostic assessment initiated 
by a physician or referral in the presence of prostate cancer symptoms. Delays of any 
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kind were generally rare in all but two intervals. System delays occurred most often 
(25%) during the interval between biopsy/TRUS to receipt of the pathology report. 
Patient delays occurred most often (14.8%) during the interval between the date patients 
were informed of their results to the decision to start treatment. 
Radical prostatectomy (48.4%) and radiotherapy (26.8%) accounted for three 
quarters (75.2%) of the treatment modalities chosen by patients. 
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Table 4.1 : Characteristics of the Study's Sample 
Characteristics n (%) 
Community of residence 
Urban (<10 000) 167 (49.0) 
Rural ( '?I 0 000) 174 (5 1.0) 
Age 
Young (<70) 278 (8 1.5) 
Old (?:10) 63 (18.5) 
Season 
Spring 78 (23.0) 
Summer 81 (23.9) 
Fall 80 (23.6) 
Winter 100 (29.5) 
Referral reason 
PSAIDRE!Family 336 (98.5) 
Other 5 ( 1.5) 
Prostate volume 
Normal (<30cm3) 61 (33 .7) 
Not normal ( ;80cm3) 120 (66.3) 
DREa 
Normal 65 (19.1) 
Not normal 276 (80.9) 
PSA" 
Low ( < I 0 ng/ml) 283 (83.0) 
Medium (I 0-19.9 ng/ml) 40 (11.7) 
High ( ~0 ng/ml) 18 (5.3) 
Had Diabetes 
No 21 1 (88.7) 
Yes 27 (11.3) 
Had CVDc 
No 100 (42.0) 
Yes 138 (58.0) 
Had musculoskeletal condition 
No 161 (67.6) 
Yes 77 (32.4) 
Had Gl!Hemia0 
No 178 (74.8) 
Yes 60 (25 .2) 
Had hypertension 
No 206 (86.6) 
Yes 32 (13.4) 
Had other comorbidity 
No 222 (93.3) 
Yes 16 (6.7) 
Has prostate cancer 
No - No Cancer 184 (54.0) 
Yes- Has Cancer 157 (46.0) 
Stage* 
Early-Stage (Gleason :S;6, g'2a, PSA < 10) 69 (44.0) 
Late-Stage (Gleason >6, >T2a, PSA ;::iO) 88 (56.0) 
Clinical risk* 
Low (g'2a) 72 (45.9) 
Intermediate (T2b) 22 (14.0) 
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High (>T2b) 63 (40. 1) 
Gleason* 
Low ( ~6) 69 (43.9) 
Medium (7) 62 (39.5) 
High (>7) 26 (I 6.6) 
Treatment modality* 
Radical prostatectomy 76 (48.4) 
Radiotherapy 42 (26.8) 
Watchful waiting (includes active surveillance) 28 (17.8) 
Other (brachytherapy, palliative care, hom1one therapy) II (7.0) 
Delay in GPe referral to first visit with urologist 
Patient I (0.3) 
Physician I (0.3) 
System 0 (0) 
No delay 339 (99 .6) 
Delay in patient decision to biopsy to date of biopsy 
Patient I (0.3) 
Physician I (0.3) 
System 0 (0.0) 
No delay 339 (99.6) 
Delay in date of biopsy to date physician receives pathology report 
Patient 0 (0) 
Physician 0 (0) 
System 84 (24.6) 
No delay 257 (75.4) 
Delay in date pathology received to date patient was informed of results 
Patient I (0.3) 
Physician 0 (0) 
System 2 (0.6) 
No delay 338 (99.1) 
Delay in date patient was informed to decision to first treatment* 
Patient 50 (3 1.9) 
Physician I (0.6) 
System 7 (4.5) 
No delay 99 (63 .0) 
Delay in decision to treatment to first treatment* 
Patient 8 (5.0) 
Physician 0 (0) 
System 0 (0) 
No delay 149 (95.0) 
a DRE - Digital Rectal Examination 
b PSA - Prostate Specific Antigen 
c CVD - Cardiovascular Disease 
d GI - Gastrointestinal Disease 
eGP - General Practitioner 
*Includes individuals with prostate cancer only 
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4.2.2 Wait Times 
Table 4.2 describes the wait times experienced by men in the study. The shortest 
median wait time was 19 days from the date of the biopsy/TRUS to the urologist's receipt 
of the pathology report. The longest median wait time was 68 days from referral by the 
general practitioner to the first visit with the urologist. It took four weeks (median 28 
days) from the decision to biopsy/TRUS until the date ofbiopsy/TRUS. The median wait 
time from date of referral to first treatment (all modalities) was 188 days. The longest 
median wait from referral to start of specific treatment modality was for radical 
prostatectomy (203 days), and the shortest was for watchful waiting (128 days). 
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Table 4.2: Description of Wait Time Intervals 
Wait Time Intervals Mean (SD) Median Range (min, max) 90
1
h Percentile 
(days) (days) (days) (days) 
General practitioner referral to first visit with urologist 78.0 (54.7) 68.0 310.0 (0, 310.0) 146.6 
Patient decision to biopsy to date of biopsy 33.4 (29.5) 28.0 151.0 (0, 151.0) 69.0 
Date of biopsy to date physician receives pathology report 20.5 (9 .9) 19.0 87.0 (1 .0, 88.0) 32.0 
Date pathology received to date patient was informed of results 40.6 (55 .6) 20.0 385.0 (0, 385.0) 119.8 
Decision to treat to first treatment* 40.8 (45.7) 30.0 272.0 (0, 272.0) 9 1.4 
Date of referral to when patient was informed of results 172.3 (85.9) 154.0 545 .0 (35 .0, 580.0) 292.2 
Date of referral to first treatment (all modalities)* 193.3 (80.5) 188.0 456.0 (35.0, 49 1.0) 289.6 
!{~::r;:B£r.e 7~?7%4~~-vp .~:t-·<"'""~ , ',~'>~q;,; :f ~:,~;,0::2li~v;;~~~f~~il¥~1~!l'~;P''~~m;w,IIIIJD 
::: '"*'"
00 
" \•• Pi'!' ~ > ,;._,'0.'9<;:<., -...N ' + *lfi}:"~ :>,/N> i,'\ ":Q>'@ """'"'@J'(::>~ :'l& 
Date of referral to radical prostatectomy* 210.4 (67.8) 203.0 416.0 (75 .0, 49 1.0) 289.6 
Date of referral to radiotherapy* 191.7 (81.1) 172.5 392.0 (91.0, 483.0) 288.7 
Date of referral to watchful waiting (includes active 157.0 (83 .9) 128.0 300.0 (35.0, 335.0) 285.2 
surveillance)* 
Date of referral to other treatment (brachytherapy, palliative care, 170.5 (119.8) 154.0 395.0 (40.0, 435.0) 412.0 hormone therapy)* 
Date of diagnosis to radical prostatectomy* 62.6 (41.2) 46.5 221.0 (2.0, 223 .0) 121.7 
Date of biopsy to radical prostatectomy* 102.2 (45.0) 85.0 224.0 (35.0, 259) 170.1 
Date of biopsy to date patient was informed ofresu1ts 61.1 (57.6) 40.0 391 .0 (13 .0, 404.0) 140.4 
*Includes individuals with prostate cancer only 
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4.2.3 Benchmarks 
Table 4.3 describes the proportion of individuals who met and did not meet the 
local, national, and international benchmarks. Thirteen percent (13%) to 62.5% of men 
met the local NL benchmarks for referral to first treatment and date of biopsy to date 
pathology report received respectively. Thus, less than half the patients in the study 
sample met local benchmarks, with one exception: almost two-thirds of the biopsy 
reports were received within the local benchmark. 
Low-risk individuals (91.3%) from NL were most likely to have met the SWAT 
Initiative benchmark for wait time between decision to operate until day of surgery. On 
the other hand, most urgent-patients (96.6%) did not meet the UKNHS benchmark for 
wait time between general practitioner referral to first treatment. With the exception of 
benchmarks set by the SWAT Initiative and the study by Moul et al. (2004) as cited in 
Saad et al. (2006), few men met the benchmarks suggested by other groups. In each of 
the subsequent sections, a discussion of the benchmarks, followed by a discussion ofthe 
predictors, is presented. 
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National and International Benchmarks 
Did Not 
NL Expert Opinion, 2010 
Date of biopsy to date pathology report 
received ::;2 1 128 (37.5) NL Expert Opinion, 20 1 0 2 13 (62.5) 
NL Expert Opinion, 20 I 0 53 (15.8) 282 (84.2) 
NL Expert Opinion, 2010 46 (30.3) 106 (69.7) 
56(16.4) 285 (83.6) 
24 (7.0) 31 7 (93.0) 
3 (3.4) 84 (96.6) 
15 (35.7) 27 (64.3) 
uuo•u•c• .. Surgical Wait Times (SWAT) 
2006 63 
auo•u•c•u Surgical Wait Times (SWAT) 
2006 6 1 
68 
Esmail and Walker, 2005 23 
* Includes individuals with prostate cancer only 
a U were defined Gleason score "8 Clinical and a PSA ;::1. 0 
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4.2.4 Interval 1: GP Referral to First Visit With the Urologist 
Table 4.4 describes the characteristics of men who met and did not meet the 
benchmark for the wait time from date of referral to first visit with the urologist. A 
significantly larger proportion of men who met the benchmark were urban residents. 
There were no other significant differences between men who met and did not meet this 
benchmark. 
Men from rural communities were 0.60 times as likely (or 1.67 times less likely) 
to have met the benchmark than urban men. The age and urgency variables (PSA on 
referral) were not significant predictors in determining whether or not men met the 
benchmark (Table 4.5). 
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Table 4.4: Characteristics of Men who Met and Did Not Meet The Benchmark from Date 
ofReferral to First Visit with the Urologist (n=341) 
Met Did not meet p-value 
Characteristics benchmark benchmark 
n (% ) n (% ) 
Community of residence 0.049 
Urban ( ?1 0 000) 80 (55 .2) 87 (44.4) 
Rural (< 10 000) 65 (44.8) 109 (55.6) 
Age 0.080 
Young (<70) 11 2(77.2) 166 (84.7) 
Old ( 2!0) 33 (22.8) 30 (15.3) 
Season on referral 0.056 
Spring 38 (26.2) 40 (20.4) 
Summer 29 (20.0) 52 (26.5) 
Fall 27 (18.6) 53 (27 .0) 
Winter 51 (35.2) 51 (26.0) 
Referral reason 0.426 
PSAIDRE!Family 142 (97.9) 194 (99.0) 
Other 3 (2. 1) 2 (1.0) 
PSA b on referral 0.133 
Low(< 10 nglml) 114 (78.6) 169 (86.2) 
Medium (10- 19.9 ng/ml) 20 (13.8) 20 (10.2) 
High (~0 ng/ml) 11 (7.6) 7 (3.6) 
Had diabetes 0.307 
No 131 (90.3) 183 (93.4) 
Yes 14 (9.7) 13 (6.6) 
Had CVDc 0.943 
No 86 (59.3) 117 (59.7) 
Yes 59 (40.7) 79 (40.3) 
Had musculoskeletal condition 0.908 
No 42 (4 1.6) 58 (42.3) 
Yes 59 (58.4) 79 (57.7) 
Had Gl/Hemia0 0.883 
No 120 (82.8) 161 (82 .1 ) 
Yes 25 (17.2) 35(17.9) 
Had hypertension 0.327 
No 134 (92.4) 175 (89.3) 
Yes 11 (7 .6) 21 {10.7) 
Had other comorbidity 0.350 
No 140 (96.6) 185 (94.4) 
Yes 5 (3 .4) 11 (5 .6) 
Delay in GPe referral to first visit with urologist 0.475 
Patient 0 (0) 1 (0.5) 
Physician 0 (0) 1 (0.5) 
System 0 (0) 0 (0) 
No delay 145 (100) 194 (99.0) 
a DRE - Digital Rectal Examination 
b PSA - Prostate Specific Antigen 
c CVD - Cardiovascular Disease 
ct GI - Gastrointestinal Disease 
e GP - General Practitioner 
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Table 4.5 : Predictors of Men Who Met the Benchmark From Date of Referral to First 
Visit (n=341) 
Variable Odds Ratio 95% Confidence p-value Interval 
Community of residence 0.025 
Urban ( ;::i 0 000) 1.00 
Rural (< lO 000) 0.60 0.39 - 0.94 
Age 0.198 
Young (<70 years) 1.00 
Old ( ~70 years) 1.46 0.82 - 2.61 
PSA on referral 0.181 
Low(< 10 ng/ml) 1.00 
Medium (10-19.9 ng/ml) 1.36 0.38 - 1.36 0.382 
High (~0 ng/ml) 2.44 0.89 - 6.69 0.084 
4.2.5 Interval II : Decision to Biopsy to Biopsy 
Table 4.6 describes the characteristics of men who met and did not meet the 
benchmark for the wait time from decision to have a biopsy to biopsy/TRUS. A 
significantly larger proportion of men who met the benchmark were rural residents. 
Furthermore, significant differences were detected for men that did not meet the 
benchmark who had neither hypertension nor other comorbidity. There were no other 
significant differences between men who met and did not meet this benchmark. 
After controlling for other predictors (hypertension and comorbidity), men from 
rural communities were 2.02 times more likely to have met the benchmark than urban 
men. Age and urgency variables (PSA on referral and DRE) were not significant 
predictors in determining whether or not men met the benchmark (Table 4. 7). 
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Table 4.6: Characteristics of Men who Met and Did Not Meet The Benchmark from Date 
of First Visit with the Urologist to Date ofBiopsy/TRUS (n=341) 
Met Did not meet p-vaiue 
Characteristics benchmark benchmark 
n (%) n (%) 
Community of residence O.OOI 
Urban (;:d 0 000) 42 (36.8) I25 (55. I) 
Rural {<10 000) 72 (63.2) I02 (44.9) 
Age 0.144 
Young {<70) 88 (77.2) 190 (83.7) 
Old (210) 26 (22.8) 37 (16.3) 
Season on referral 0.095 
Spring 23 (20.2) 55 (24.2) 
Summer 20 (17.5) 61 (26.9) 
Fall 29 (25.4) 51 (22.5) 
Winter 42 (36.8) 60 (26.4) 
Referral reason 0.542 
PSAIDRE!Family I12 (98.2) 224 (98.7) 
Other 2 (1.8) 3 (1.3) 
DRE• 0.937 
Normal 22 {19.3) 43 {18.9) 
Not normal 92 (80.7) I 84 (81.1) 
PSA 0 on referral 0.114 
Low ( < I 0 ng/ml) 90 (78.9) 193 (85.0) 
Medium (10-19.9 ng/ml) 14 (12.3) 26 {1I .5) 
High ( ~0 ng/ml) 10 (8 .8) 8 (3.5) 
Had diabetes 0.091 
No I0 1 (88.6) 2 13(93.8) 
Yes 13(11.4) 14 (6.2) 
Had CVDc 0.975 
No 68 (59.6) 135 (59.5) 
Yes 46 (40.4) 92 (40.5) 
Had musculoskeletal condition 0.478 
No 62 (70.5) 99 (66.0) 
Yes 26 (29.5) 51 (34.0) 
Had GI/Hemiad 0.535 
No 96 (84.2) 185 (81.5) 
Yes 18 {15.8) 42(18.5) 
Had hypertension 0.037 
No 98 (86.0) 211 (93 .0) 
Yes 16 (14.0) 7 (3 .1) 
Had other comorbidity 0.047 
No 105 (92.1) 220 (96.9) 
Yes 9 (7 .9) 7 (3.1) 
Delay in GPe referral to first visit with urologist 0.287 
Patient 0 (0) I (0.4) 
Physician 1 (0.9) 0 (0) 
System 0 (0) 0 (0) 
No delay 113 (99. 1) 226 (99.6) 
Delay in patient decision to biopsy to biopsy 0.603 
Patient 0 (0) I (0.4) 
Physician 0 (0) I (0.4) 
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System 
No delay 
a DRE - Digital Rectal Examination 
b PSA - Prostate Specific Antigen 
c CVD - Cardiovascular Disease 
d GI - Gastrointestinal Disease 
e GP - General Practitioner 
I 
o (0) I o (0) I 
114 (100.0) 225 (100.0) 
Table 4.7: Predictors of Men Who Met the Benchmark From Decision to Biopsy until 
Biopsy (n=341) 
Variable Odds Ratio 95% Confidence p-value Interval 
Conununity of residence 0.003 
Urban ( ;::i 0 000) 1.00 
Rural (< I 0 000) 2.02 1.27- 3.22 
Age 0.254 
Young (<70 years) 1.00 
Old ( ;:::70 years) 0.702 0.78 - 2.62 
PSA on referral 0.378 
Low ( < 10 ng/ml) 1.00 
Medium {I 0-19.9 ng/ml) 1.36 0.49 - 2.15 0.935 
High ( ;::::20 ng/rnl) 2.44 0.75 - 5.51 0.164 
DRE 0.686 
Normal 1.00 
Abnormal 0.88 0.49 - 1.60 
4.2.6 Interval III: Biopsy to Receipt of Pathology Report 
Table 4.8 describes the characteristics of men who met and did not meet the 
benchmark for the wait time from time of the biopsy until the receipt of the pathology 
report by the urologist. A significantly larger proportion of men who met the benchmark 
did not encounter a systemic delay in comparison to men who did have a systemic delay. 
There were no other significant differences detected between men who met and did not 
meet this benchmark. 
After controlling for predictors (system delay in the interval between the date of 
biopsy and receipt of pathology report), age, urgency variables (PSA on referral and 
DRE), and community of residence were not significant predictors in determining 
whether or not men met the benchmark (Table 4.9). 
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Table 4.8: Characteristics of Men who Met and Did Not Meet The Benchmark from Date 
of Biopsy to Date Biopsy Results Received by Urologist (n=341) 
Met Did not meet 
Characteristics benchmark benchmark p-value 
n (%) n (%) 
Community of residence 0.878 
Urban (~0 000) 105 (49.3) 62 (48.4) 
Rural (<10 000) 108 (50.7) 66 (5 1.6) 
Age 0.919 
Young (<70) 174 (81.7) I 04 (81.3) 
Old (80) 39 (18.3) 24 (18.8) 
Season on referral 0.84 1 
Spring 52 (24.4) 26 (20.3) 
Summer 50 (23.5) 31 (24.2) 
Fall 48 (22.5) 32 (25.0) 
Winter 63 (29.6) 39 (30.5) 
Referral reason 0.909 
PSAIDRE/Family 210 (98.6) 126 (98.4) 
Other 3 (1.4) 2 ( 1.6) 
Prostate volume 0.43 1 
Normal (<30cm3) 36 (31.6) 25 (37.3) 
Not normal ( ;80cm3) 78 (68.4) 42 (62.7) 
DREa 0.690 
Normal 42 (19.7) 23 (18.0) 
Not normal 171 (80.3) 105 (82.0) 
PSA 0 on Referral 0.452 
Low ( < 10 ng/ml) 181 (85.0) 102 (79.7) 
Medium (10-19.9 ng/ml) 22 (10.3) 18 (14. 1) 
High ( ;::::20 ng/ml) 10 (4.7) 8 (6.3) 
Had diabetes 0.194 
No 193 (90.6) 121 (94.5) 
Yes 20 (9.4) 7 (5.5) 
Had CVDc 0.682 
No 125 (58.7) 78 (60.9) 
Yes 88 (41.3) 50(39. 1) 
Had musculoskeletal condition 0.952 
No 106 (67.5) 55 (67.9) 
Yes 51 (32.5) 26 (32.1) 
Had GI/Hemia0 0.467 
No 178 (83.6) 103 (80.5) 
Yes 35(16.4) 25 (19.5) 
Had hypertension 0.996 
No 193 (90.6) 116 (90.6) 
Yes 20 (9.4) 12 (9.4) 
Had other comorbidity 0.595 
No 202 (94.8) 123 (96.1) 
Yes 11 (5.2) 5 (3 .9) 
Has prostate cancer 0.643 
No - No Cancer 117 (54.9) 67 (52.3) 
Yes -Has Cancer 96(45. 1) 61 (47.7) 
Delay in GPe referral to first visit with urologist 0.322 
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Patient 1 (0.5) 0 (0) 
Physician 0 (0) 1 (0.8) 
System 0 (0) 0 (0) 
No delay 212 (99.5) 127 (99.2) 
Delay in patient decision to biopsy to biopsy 0. 188 
Patient 0 (0) 1 (0.8) 
Physician 0 (0) 1 (0.8) 
System 0 (0) 0 (0) 
No delay 21 3 (100.0) 126 (98.4) 
Delay in date of biopsy to receipt of pathology report 0.027 
Patient 0 (0) 0 (0) 
Physician 0 (0) 0 (0) 
System 61 (28.6) 23 (18.0) 
No delay 152 (7 1.4) 103 (82.0) 
a DRE - Digital Rectal Examination 
b PSA - Prostate Specific Antigen 
c CVD - Cardiovascular Disease 
d GI - Gastrointestinal Disease 
e GP - General Practitioner 
*Includes individuals with prostate cancer only 
Table 4.9: Predictors of Men Who Met the Benchmark From Biopsy Until Biopsy Results 
Were Received (n=341) 
Variable Odds Ratio 95% Confidence p-value Interval 
Community of residence 0.964 
Urban ( :2'i 0 000) 1.00 
Rural (<10 000) 0.99 0.64 - 1.54 
Age 0.752 
Young (<70 years) 1.00 
Old ( ~70 years) 1.1 0 0.61 - 2.00 
PSA on referral 0.457 
Low(< 10 ng/ml) 1.00 
Medium (1 0-19.9 ng/ml) 0.69 0.34 - 1.36 0.272 
High (~20 ng/ml) 0.69 0.26 - 1.85 0.458 
DRE 0.752 
Normal 1.00 
Abnormal 0.9 1 0.51 - 1.62 
4.2.7 Interval IV: Receipt of Pathology Report to Notification of Results 
Table 4. 10 describes the characteristics of men who met and did not meet the 
benchmark for the wait time from when the urologist receives the pathology report to 
when the patient is informed of his results. A significantly larger proportion of men who 
met the benchmark lived in rural communities, had cancer, and did not have a delay in 
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the interval patient decision to biopsy to biopsy being performed. There were no other 
significant differences between men who met and did not meet this benclunark. 
After controlling for other predictors (delay in the interval patient decision to 
biopsy to biopsy being performed), men who were from a rural area were 1.89 times 
more likely to have met the benclunark than urban men. Also, men who had cancer were 
2.15 times more likely to have met the benclunark than men who did not have cancer. 
The age and urgency variables (PSA on referral, has prostate cancer, and ORE) were not 
significant predictors in whether or not men met the benclunark (Table 4. 11 ). 
Table 4.10: Characteristics of Men who Met and Did Not Meet The Benclunark from 
When Biopsy Results Available to When Patient was Informed by Urologist (n=341) 
Met Did not p-value 
Characteristics benchmark meet 
n (%) benchmark 
n (%) 
Community of residence 0.038 
Urban ( ::::1. 0 000) 19(35.8) 148 (52. 1) 
Rural (<10 000) 34 (64.2) 140 (47.9) 
Age 0. 105 
Young (<70) 39 (73.6) 239 (83.0) 
Old (?5'0) 14 (26.4) 49 (1 7.0) 
Season on referral 0.252 
Spring 8 (15.1) 70 (24.3) 
Summer 14 (26.4) 67 (23 .3) 
Fall 17 (32.1) 63 (2 1.9) 
Winter 14 (26.4) 88 (30.6) 
Referral reason 0.573 
PSAIDRE!Family 52(98.1) 284 (98.6) 
Other I ( 1.9) 4 (1.4) 
Prostate volume 0.222 
Normal (<30cm3) 14 (43.8) 47 (32.4) 
Not normal ( ;:30cm3) 18 (56.3) 98 (67.6) 
DRE" 0.739 
Normal II (20.8) 53 (18.8) 
Not normal 42 (79.2) 229 (81 .2) 
PSAb on referral 0.283 
Low ( < 10 ng/ml) 40 (75.5) 238 (84.4) 
Medium (1 0-19.9 ng/ml) 9 (17.0) 31 (11.0) 
High ( ;::::20 ng/ml) 4 (7.5) 13 (4.6) 
Had diabetes 0.403 
No 47 (88.7) 267 (92.7) 
Yes 6 (11.3) 21 (7.3) 
Had CVDc 0.09 1 
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No 26 (49.1) 177(6 1.5) 
Yes 27 (50.9) 111 (38.5) 
Had musculoskeletal condition 0.662 
No 28 (65.1) 133 (68.6) 
Yes 15 (34.9) 61 (31.4) 
Had GUHemiad 0.5 11 
No 42 (79.2) 239 (83 .0) 
Yes 11 (20.8) 49 (1 7.0) 
Had hypertension 0.799 
No 49 (92.5) 260 (90.3) 
Yes 4 (7.5) 28 (9 .7) 
Had other comorbidity 0.723 
No 50 (94.3) 275 (95.5) 
Yes 3 (5.7) 13 (4.5) 
Has prostate cancer 0.0 13 
No - No Cancer 20 (37.7) 159 (56.4) 
Yes - Has Cancer 33 (62.3) 124 (43.6) 
Delay in GPe referral to first visit with urologist 0.831 
Patient 0 (0) 1 (0.4) 
Physician 0 (0) 1 (0.4) 
System 0 (0) 0 (0) 
No delay 53 (100.0) 286 (99.3) 
Delay in patient decision to biopsy to biopsy 0.004 
Patient 1 ( 1.9) 0 (0) 
Physician 1 ( 1.9) 0 (0) 
System 0 (0) 0 (0) 
No delay 53 (96.2) 288 (100.0) 
Delay in biopsy to receipt of pathology report 0.714 
Patient 0 (0) 0 (0) 
Physician 0 (0) 0 (0) 
System 12 (22.6) 72 (25 .0) 
No delay 41 (77.4) 216 (75.0) 
Delay in pathology report to patient informed of results 0.757 
Patient 0 (0) I (0.3) 
Physician 0 (0) 2 (0 .7) 
System 0 (0) 0 (0) 
No delay 53 (1 00.0) 285 (99.0) 
a DRE - Digital Rectal Examination 
b PSA - Prostate Specific Antigen 
c CVD - Cardiovascular Disease 
d GI - Gastrointestinal Disease 
e GP - General Practitioner 
* Includes individuals with prostate cancer only 
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Table 4.11: Predictors of Men Who Met the Benchmark From Biopsy Results Were 
Received to When the Patient Were Informed ofTheir Results (n=341) 
Variable Odds Ratio 95% Confidence p-value Interval 
Conununity of residence 0.045 
Urban (;:::! 0 000) 1.00 
Rural (<10 000) 1.89 1.01 - 3.52 
Age 0.230 
Young (<70 years) 1.00 
Old ( ";::.70 years) 1.57 0.75 - 3.30 
Has prostate cancer 0.015 
No Cancer 1.00 
Has Cancer 2.15 1.16 - 3.97 
PSA on referral 0.644 
Low (< 10 ng/ml) 1.00 
Medium (10-19.9 ng/ml) 1.51 0.64 - 3.57 0.349 
High ( ";::.20 ng/ml) I. II 0.33 - 3.75 0.863 
DRE 0.358 
Normal 1.00 
Abnormal 0.70 0.33 - 1.50 
4.2.8 Interval V: Decision to Treat to First Treatment 
Table 4.12 describes the proportion of individuals who met and did not meet the 
benchmark for the wait time from decision to treat to the time of first treatment. This 
interval only includes men with prostate cancer. A significantly larger proportion of men 
who met the benchmark were old, had a low PSA, were early-stage, had low clinical-risk 
and low Gleason scores, and chose watchful waiting for their first treatment. There were 
no other significant differences between men who met and did not meet this benchmark. 
After controlling for predictors (treatment modality), older men were 5.82 times 
more likely to have met the benchmark than younger men. Men with a medium Gleason 
score were 5.00 times less likely (0.20 as likely) to have met the benchmark than men 
with a low Gleason. High Gleason and community of residence score were not 
significant predictors in determining whether or not men met the benchmark (Table 4.13 ). 
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Table 4.1 2: Characteristics of Men With Prostate Cancer Who Met and Did Not Meet 
The Benchmark from Decision ofFirst Treatment to First Treatment* (n=l57) 
Met Did not meet 
Characteristics benchmar k benchmark p-value 
n (%) n (% ) 
Community of residence 0.553 
Urban ( ?d O 000) 22 (47.8) 54 (50.0) 
Rural (<10 000) 27 (52.2) 54 (50.0) 
Age 0.000 
Young (<70) 20 (40.8) 93 (86.1) 
Old (?!10) 29 (59.2) 15 (13.9) 
Season on referral 0.299 
Spring II (22.4) 19 (17.6) 
Summer 7 (14.3) 30 (27 .8) 
Fall 12 (24.5) 20 (18.5) 
Winter 19 (38.8) 39(36.1) 
Referral reason 1.000 
PSAIDRE/Family 49 (100.0) 107 (99.1) 
Other 0 (0) I (0.9) 
Prostate volume 0.462 
Normal (<30cm3) 12 (46.2) 23 (37.7) 
Not normal ( ;:30cm3) 14 (53.8) 38 (62.3) 
DREa 0.30 1 
Normal 10(20.4) 15 (13.9) 
Not normal 39 (79.6) 93(86.1) 
PSAb on referral 0.0 12 
Low ( < 10 ng/ml) 37 (75.5) 86 (79.6) 
Medium (1 0-19.9 ng/ml) 4 (8 .2) 18 (16.7) 
High ( ~0 ng/ml) 8 (16.3) 4 (3.7) 
Had diabetes 0.836 
No 43 (87.8) 96 (88.9) 
Yes 6 (12.2) 12(11.1) 
Had CVDc 0.200 
No 29 (59.2) 52(48.1) 
Yes 20 (40.8) 56 (5 1.9) 
Had musculoskeletal condition 0.830 
No 20 (64.5) 54 (66.7) 
Yes 11 (35.5) 27 (33 .3) 
Had GI!Hemiad 0.794 
No 40 (81.6) 90 (83.3) 
Yes 9 (18.4) 18(16.7) 
Had hypertension 0.836 
No 43 (87.5) 96 (88.9) 
Yes 6 (12.2) 12 (11.1) 
Had other comorbidity 1.000 
No 46 (93.9) 101 (93.5) 
Yes 3 (6.1) 7 (6.5) 
Stage 0.010 
Early Stage (Gleason ::;;6, ::T2a, PSA < 10) 29 (56.5) 40 (36.8) 
Late Stage (Gleason >6, >T2a, PSA ;::10) 20 (43.5) 68 (63 .2) 
Clinical risk 0.010 
Low ( ::T2a) 29 (59.2) 40(37.0) 
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Intermediate (T2b) 11 (22.4) 51(47.2) 
High (>T2b) 9 (18.4) 17(15.7) 
Gleason 0.010 
Low (:::;6) 29 (59.2) 40 (37.0) 
Medium (7) 11 (22.4) 51 (47.2) 
High (>7) 9 (18.4) 17 (15.7) 
Treatment modality 0.000 
Radical prostatectomy 9 (18.4) 67 (62.6) 
Watchful waiting (includes active surveillance) 26(53 .1 ) 1 (0.9) 
Radiotherapy 7 (14.3) 35 (32.7) 
Other (brachytherapy, palliative care, hormone therapy) 7 (14.3) 4 (3 .7) 
Delay in GPe referral to first visit with urologist 0.264 
Patient 0 (0) 0 (0) 
Physician 1 (2.0) 0 (0) 
System 0 (0) 0 (0) 
No delay 48 (98.0) 107 (1 00.0) 
Delay in patient decision to biopsy to biopsy 0.632 
Patient 0 (0) 1 (0.9) 
Physician 0 (0) I (0 .9) 
System 0 (0) 0 (0) 
No delay 49 (100.0) 106 (98.1) 
Delay in biopsy to receipt of pathology report 0.556 
Patient 0 (0) 0 (0) 
Physician 0 (0) 0 (0) 
System 13 (26.5) 24 (22.2) 
No delay 36 (73.5) 84 (77.8) 
Delay in pathology report to patient informed of results 1.000 
Patient 0 (0) I (0.9) 
Physician 0 (0) 0 (0) 
System 0 (0) 0 (0) 
No delay 49 (100.0) 107 (99. 1) 
Delay in patient informed to decision to treat* 0.28 1 
Patient 12 (24.5) 38 (35.2) 
Physician 0 (0) 1 (0.9) 
System I (2.0) 6 (5 .6) 
No delay 36 (73.5) 63 (58.3) 
Delay in decision to treat to treatment* 0.058 
Patient 0 (0) 8 (7.4) 
Physician 0 (0) 0 (0) 
System 0 (0) 0 (0) 
No delay 49 (100.0) 100 (92.6) 
a DRE - Digital Rectal Examination 
b PSA - Prostate Specific Antigen 
c CVD - Cardiovascular Disease 
d GI - Gastrointestinal Disease 
e GP - General Practitioner 
*Includes individuals with prostate cancer only 
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Table 4.13: Predictors of Men Who Met the Benchmark From Decision to Treat to First 
Treatment* (n= 157) 
Variable Odds Ratio 95% Confidence p-value Interval 
Community of Residence 0.216 
Urban ( ;::i 0 000) 1.00 
Rural (< I 0 000) 1.62 0.76- 3.46 
Age 0.000 
Young (<70 years) 1.00 
Old ( ~70 years) 5.82 2.43 - 13.95 
Gleason 0.003 
Low ( ~6) 1.00 
Medium (7) 0.20 0.08 - 0.50 0.00 1 
High (>7) 0.52 0.19 - 1.46 0.2 17 
*Includes individuals with prostate cancer only 
4.2.9 Interval VI: GP Referral to Notification of Results to the Patient 
Table 4.14 describes the characteristics of men who met and did not meet the 
benchmark for the wait time from date of referral to notification of results. A 
significantly larger proportion of men who met the benchmark were old and had prostate 
cancer. Also, a significantly larger proportion of men who met the benchmark did not 
have a delay between the biopsy and the receipt of the pathology report than men who 
had a delay. There were no other significant differences between men who met and did 
not meet this benchmark. 
After controlling for other predictors (delay in biopsy to receipt of pathology 
report and has prostate cancer), older men were 3.12 times more likely to have met the 
benchmark than younger men. Moreover, men who had a system delay between biopsy 
to date physician receives pathology report were 0.41 times as likely (or 2.44 times less 
likely) to have met the benchmark than men who did not have a delay. Community of 
residence and urgency variables (has prostate cancer, PSA on referral, and ORE) were not 
significant predictors of men who met or did not meet the benchmark (Table 4.15). 
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Table 4.14: Characteristics of Men who Met and Did Not Meet The Benchmark from 
Date ofReferral to Notification of Results (n=341) 
Met Did not 
Characteristics benchmark meet p-value benchmark 
n (% ) 
n (%) 
Community of residence 0.867 
Urban ( 2:10 000) 28 (50.0) 139 (48 .8) 
Rural (<10 000) 28 (50.0) 146 (51.2) 
Age 0.000 
Young (<70) 36 (64.3) 242 (84.9) 
Old (;BO) 20(35.7) 43(15.1) 
Season on referral 0.25 1 
Spring 10 (17.9) 68 (23 .9) 
Summer 12 (21.4) 69 (24.2) 
Fall 11 (19.6) 69 (24.2) 
Winter 23 (41.1) 79 (27.7) 
Referral reason 0. 152 
PSAIDRE!Family 54 (96.4) 282 (98.9) 
Other 2 (3.6) 3 (1.1) 
DRE• 0.904 
Normal 11 (19.6) 54(18.9) 
Not normal 45 (80.4) 23 1 (81.1) 
PSA0 on referral 0.003 
Low(< 10) 40 (71.4) 243 (85 .3) 
Medium (10-19.9) 8 (14.3) 32 (11 .2) 
High (~0) 8 (14.3) 10(3.5) 
Had diabetes 0. 177 
No 49 (87.5) 265 (93 .0) 
Yes 7 (12.5) 20 (7.0) 
Had CVDc 0.920 
No 33 (58.9) 170 (59.6) 
Yes 23 (41.1) 115 (40.4) 
Had musculoskeletal condition 0.248 
No 33 (75.0) 128 (66.0) 
Yes 11 (25 .0) 66 (34.0) 
Had GI/Hemia" 0.660 
No 45 (80.4) 236 (82.8) 
Yes 11 (19.6) 49 (17.2) 
Had hypertension 0.898 
No 51 (91.1) 258 (90.5) 
Yes 5 (8.9) 27 (9.5) 
Had other comorbidity 0.733 
No 53 (94.6) 272 (95.4) 
Yes 3 (5.4) 13 (4.6) 
Has prostate cancer 
No - No Cancer 23 (41.1) 161 (55 .1) 0.034 
Yes - Has Cancer 33 (58.9) 124 (43 .9) 
Delay in GPe referral to frrst visit with urologist 0.82 1 
Patient 0 (0) 1 (0.4) 
Physician 0 (0) 1 (0.4) 
System 0 (0) 0 (0) 
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No delay 56 (100.0) 283 (100.0) 
Delay in patient decision to biopsy to biopsy 0.82 1 
Patient 0 (0) I (0.4) 
Physician 0 (0) I (0.4) 
System 0 (0) 0 (0) 
No delay 56 (1 00.0) 283 (99.3) 
Delay in biopsy to receipt of pathology report 0.049 
Patient 0 (0) 0 (0) 
Physician 0 (0) 0 (0) 
System 8 (14.3) 76 (26.7) 
No delay 48 (85.7) 209 (73.3) 
Delay in pathology report to patient informed of 0.743 
results 
Patient 0 (0) 1 (0.4) 
Physician 0 (0) 0 (0) 
System 0 (0) 2 (0 .7) 
No delay 56 (100.0) 282 (98.9) 
Delay in patient informed to decision to treat* 0.214 
Patient 6 (10.7) 44 (15.4) 
Physician 0 (0) I (0.4) 
System 3 (5.4) 4 (1.4) 
No delay 47 (83.9) 236 (82.8) 
a DRE - Digital Rectal Examination 
b PSA - Prostate Specific Antigen 
c CVD - Cardiovascular Disease 
d GI- Gastrointestinal Disease 
e GP- General Practitioner 
* Includes individuals with prostate cancer only 
Table 4.15: Predictors of Men Who Met the Benchmark From Referral to Notification of 
Results (n=341) 
Variable Odds Ratio 95% Confidence Interval p-value 
Community of residence 0.572 
Urban ( ::2i 0 000) 1.00 
Rural ( < 10 000) 0.84 0.46 - 1.55 
Age 0.002 
Young (<70 years) 1.00 
Old ( "2:.70 years) 3. 12 1.54 - 6.31 
Has prostate cancer 0.088 
No Cancer 1.00 
Has Cancer 1.70 1.1 6 - 3.97 
Delay in date of biopsy to date 0.037 
physician receives pathology report 
No Delay 1.00 
System Delay 0.41 0.18 - 0.95 
PSA on referral 0.072 
Low (<10) 1.00 
Medium (10-19.9) 1.09 0.44 - 2.70 0.845 
High ("2:.20) 3.41 1.20 - 9.78 0.022 
DRE 0.232 
Normal 1.00 
Abnormal 0.70 0.29 - 1.36 
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4.2.10 Interval VII: GP Referral to First Treatment 
Table 4.16 describes the characteristics of men who met and did not meet the 
benchmark for the wait time between referral to first treatment. A significantly larger 
proportion of men who met the benchmark were urban, young, and chose watchful 
waiting as their first treatment. There were no other significant differences between men 
who met and did not meet this benchmark. 
After controlling for predictors (treatment modality), older men were 3.53 times 
more likely to have met the benchmark than younger men. Also, urgency variable 
(Gleason) and community of residence were not significant predictors of whether or not 
men met the benchmark (Table 4.17). 
Table 4.16: Characteristics of Men who Met and Did Not Meet The Benchmark from 
Date ofReferral to First Treatment*(n=157) 
Met Did not 
Characteristics benchmark meet p-value benchmark 
n (%) 
n (%) 
Community of residence 0.023 
Urban (?:10 000) 15 (71.4) 61 (44.9) 
Rural (<10 000) 6 (28.6) 75(55 .1) 
Age 0.008 
Young (<70) II (52.4) 111 (81.6) 
Old (80) 10 (47.6) 25 (18.4) 
Season on referral 0.053 
Spring 5 (23.8) 25 {18.4) 
Summer 0 (0) 38 (27.2) 
Fall 5 (23.8) 27 (19.9) 
Winter 11 (52.4) 47 (34.6) 
Referral reason 0.134 
PSAIDRE/Family 20 (95.2) 136 (I 00.0) 
Other 1 ( 4.8) 0 (0) 
Prostate volume 0.187 
Normal ( <30cm3) 9 (52.9) 26 (35.6) 
Not normal ( ;80cm3) 8 (47.1) 47 (64.4) 
DRE" 0.335 
Normal 5 (23.8) 20 (14.7) 
Not normal 16(76.2) 116(85.3) 
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PSAb on referral 0.084 
Low(< 10) 18 (85 .7) 105 (77.2) 
Medium (10- 19.9) 0 (0) 22 (16.2) 
High ( ;;:::20) 3 (14.3) 9 (6.6) 
Had diabetes 0.7 12 
No 18 (85.7) 121 (89.0) 
Yes 3 (14.3) 15 (11.0) 
Had CVDc 0.584 
No 12 (57.1) 69 (50.7) 
Yes 9 (42.9) 67 (49.3) 
Had musculoskeletal condition 0.467 
No 17 (81.0) I 00 (73.5) 
Yes 4 (19.0) 36 (26.5) 
Had GI/Hemiad 0.762 
No 17 (81.0) 113 (83.1) 
Yes 4 (19.0) 23 (16.9) 
Had hypertension 1.000 
No 19 (90.5) 120 (88.2) 
Yes 2 (9.5) 16 (11.8) 
Had other comorbidity 1.000 
No 20 (95.2) 127 (93.4) 
Yes I (4.8) 9 (6.6) 
Stage* 0.1 91 
Early Stage (Gleason ~6, ::T2a, PSA < 10) 12 (57.1) 57 (41.9) 
Late Stage (Gleason >6, >T2a, PSA ;::1. 0) 9 (42.9) 79 (58.1) 
Clinical risk* 0.051 
Low (g'2a) 14(66.7) 58 (42.6) 
Intermediate (T2b) 0 (0) 22 (16.2) 
High (>T2b) 7 (33.3) 56 (41.2) 
Gleason* 0.1 17 
Low (~6) 12 (57. 1) 57 (41.0) 
Medium (7) 4 (19.0) 58 (42.6) 
High (>7) 5 (23.8) 21(15.4) 
Treatment modality* 0.000 
Radical prostatectomy 5 (23.8) 71 (52.6) 
Watchful waiting (includes active surveillance) II (52.4) 16 (I 1.9) 
Radiotherapy 0 (0) 42(31.J) 
Other (brachytherapy, palliative care, hormone therapy) 5 (23.8) 6(4.4) 
Delay in GPe referral to ftrst visit with urologist 0.855 
Patient 0 (0) 1 (0.7) 
Physician 0 (0) 1 (0. 7) 
System 0 (0) 0 (0) 
No delay 21 (100.0) 134 (98.5) 
Delay in patient decision to biopsy to biopsy 0.855 
Patient 0 (0) I (0. 7) 
Physician 0 (0) 1 (0. 7) 
System 0 (0) 0 (0) 
No delay 21 (100.0) 134 (98.5) 
Delay in biopsy to receipt of pathology report 0.784 
Patient 0 (0) 0 (0) 
Physician 0 (0) 0 (0) 
System 4(19.0) 33 (24.3) 
No delay 17(81.0) 103 (75.7) 
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Delay in pathology report to patient infom1ed of results 1.000 
Patient 0 (0) I (0.7) 
Physician 0 (0) 0 (0) 
System 0 (0) 0 (0) 
No delay 21 (100.0) 135 (99.3) 
Delay in patient informed to decision to treat 0.495 
Patient 5 (23.8) 45 (33 .1) 
Physician 0 (0) I (0. 7) 
System 0 (0) 7 (5.1) 
No delay 16(76.2) 83 (61.0) 
Delay in deci ion to treat to treatment* 0.599 
Patient 0 (0) 8 (5 .9) 
Physician 0 (0) 0 (0) 
System 0 (0) 0 (0) 
No delay 21 (100.0) 128 (94.1) 
a ORE - Digital Rectal Examination 
b PSA - Prostate Specific Antigen 
c CVD - Cardiovascular Disease 
d GI - Gastrointestinal Disease 
e GP - General Practitioner 
*Includes individuals with prostate cancer only 
Table 4.17: Predictors of Men Who Met the Benchmark From Referral to First 
Treatment* (n=157) 
Variable Odds Ratio 95% Confidence Interval p-value 
Community of residence 0.999 
Urban ( ;::i 0 000) 1.00 
Rural (<10 000) 1.00 0.45 - 2.24 
Age 0.003 
Young (<70 years) 1.00 
Old ( ;::::70 years) 3.53 1.52 - 8.19 
Gleason 0.865 
Low (~6) 1.00 
Medium (7) 1.04 0.42 - 2.55 0.940 
High (>7) 1.34 0.45-4.02 0.600 
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CHAPTERS 
DISCUSSION 
This study used a retrospective chart audit data collection to examine wait times 
for prostate cancer care in NL. The chart audits were designed to analyze wait times for 
prostate cancer patients awaiting various levels of care. Key findings from the study 
included: (a) patients in Newfoundland and Labrador waited longer than recommended 
wait time benchmarks set by local experts, surgical committees, and governments during 
most intervals in the prostate cancer care pathway. The longest wait existed between the 
GP referral and the first visit with the urologist (68 days [0, 31 0.0]). Patients experienced 
a median wait time of 188 days (35.0, 491.0) from GP referral to first treatment (all 
modalities). Even though the majority of people were found to have not met the 
benchmarks in our analysis, our results suggests some triaging of patients based on 
residency (rural patients seen faster between decision to biopsy to biopsy). However, 
there appeared to be a lack of evidence to support urologists triaging patients based on 
age or urgency throughout the prostate cancer care pathway. Patients in Newfoundland 
and Labrador are waiting longer periods than provincially generated reports currently 
indicate. 
5.1 Wait Time Intervals 
Many studies measuring wait times for prostate cancer care only examined a 
small portion of the wait intervals that patients' experience (Simonovic et al., 2001; 
Simonovic et al. , 2005; Cancer Care Ontario, 2004; Cole et al. , 2011). For instance, 
several studies in the United Kingdom examining wait time guarantees for the GP referral 
to specialist interval demonstrated that wait times have decreased in the targeted wait 
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time interval (Robinson et al., 2003; Blick C et al., 201 0). However, these studies also 
demonstrated that while targeting specific intervals may decrease wait time for that 
interval, wait times across the spectrum of care remain roughly the same. Therefore, it 
can be suggested that focusing on, and improving only one interval may shift waiting 
periods to other intervals. 
5.2 Objective 1: Wait Times in NL 
For objective one, we compared wait times obtained from the retrospective chart 
audit to benchmarks set by local experts (Table 3.2). Specifically, our objective was to 
obtain the wait times the following intervals: (a) GP referral to first visit with the 
urologist, (b) decision to biopsy to date of biopsy, (c) date of biopsy to receipt of the 
pathology report, (d) receipt of the pathology report to when the patient is informed of the 
pathology results, (e) decision to treat to date of first treatment, (f) GP referral to 
notification of results, and (g) GP referral to first treatment. 
5.2.1 Interval 1: GP Referral to First Visit 
A significantly larger proportion of men who met the benchmark were urban 
residents (55.2%). Men from rural communities were 0.60 times as likely (or 1.67 times 
less likely) to have met the benchmark than urban men. This interval between GP 
referral to first visit with the urologist was the longest median wait time in the entire 
prostate cancer pathway (68 days). GP letters requesting an appointment were typically 
sent by fax or mail. These letters ranged from thoroughly detailed (identifying all of the 
patients ' symptoms) to vague (only requesting an appointment). In some cases of 
emergencies, phone calls were made for same day appointments. Although there were 
few overt clinical notes suggesting delays during this interval, the charts did highlight the 
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need for re-mailing or re-faxing because letters were lost, which inevitably caused further 
delays to the patient. In many cases, urologists required a second PSA test, which may 
have contributed to longer wait times experienced at this interval. Since communication 
between GPs and urologists appears to have its challenges, a standardized referral system, 
that informs the urologist of the patients' symptoms and other pertinent information could 
be explored. This may not only shorten wait times at this interval, but it could allow the 
urologists to triage men who have more urgent symptoms of prostate cancer and decrease 
the likelihood of a delay. 
Comparatively, this study reported this wait interval as longer than other 
Canadian studies (Cole et al. , 2011; Kavanagh et al. , 2008; Stevens et al. , 2010). NL men 
who were referred to a urologist waited a mean of 78 days (median 68 days) compared to 
men from Toronto, Ontario (Stevens et al., 2010) who waited a mean of 40 days. 
Another study (Cole et al. , 2011) reported a mean of37.5 days in Kingston, Ontario 
whereas in Calgary, Alberta, men were reported to wait a mean of8.7 days (median 7 
days) to be seen at a rapid access clinic (Kavanagh et al., 2008). Collectively, these data 
suggest that men from NL are waiting longer than men in the other areas of the country to 
see a urologist for prostate cancer care. The Rapid Access clinic in Calgary discussed 
above was set up as a collaborative program by urologists, the Prostate Cancer Centre, 
and the Calgary Health Region, with the intention of decreasing the time it takes from GP 
referral to first visit with the urologist for men with suspected prostate cancer (Prostate 
Cancer Centre, 2011 ). As this interval is the longest wait time of the prostate cancer 
pathway for men seeking care for prostate cancer in NL, such a clinic may be of strong 
benefit in when monitoring or decreasing this wait time in NL. 
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According to the College of Physicians and Surgeons of Newfoundland and 
Labrador (2012) the number of practicing urologists in St. John's, NL has not changed 
since the completion of this study. Considering the rising trends in the incidence of 
prostate cancer thus the increasing demand for urologists in NL, it may be beneficial to 
examine benefits of increasing urology supply in NL. 
5.2.2 Interval II: Decision to Biopsy to Date of Biopsy 
A significantly larger proportion of men who met the benchmark were rural 
residents (63.2%). Men from rural conununities were 2.02 times more likely to meet the 
wait time benchmark than men from urban communities. This interval was one of the 
shortest wait times in the prostate cancer pathway (28 days). For many rural men with 
prostate cancer symptoms, biopsies were scheduled on the same-day as their first 
consultation. This practice suggests that urologists in St. John's are recognizing that rural 
patients are often waiting longer for consultation and face more barriers accessing 
urological care. Although this form oftriaging significantly shortens the wait for rural 
men, future research should examine the psychological impact of same-day biopsies and 
the possibility of this practice for urban men. This practice may be adding to the stress of 
men who may not have adequate time to make informed decisions about their health. To 
lessen the psychological stress, rural GPs referring men to urologists in St. John's, NL 
could inform their patients of the possibility ofhaving a biopsy on the same day as their 
consultation and offer information about the procedure. 
5.2.3 Interval III: Biopsy to Receipt of Pathology Report 
During this interval, 25% of all pathology reports encountered a systematic delay, 
which also was a significant predictor in detennining whether or not men met the wait 
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time benchmark between GP referral and notification of results. Reasons for these delays 
included: (a) manpower issues where a pathologist was unavailable to complete the 
report, (b) a borderline (high-grade prostatic intraepithelial neoplasia [PIN]) diagnosis 
requiring a second opinion from the Toronto General Hospital (TGH) or the Calgary 
General Hospital (CGH) ordered by the pathologist, or (c) a second opinion to confirm a 
positive cancer diagnosis from the TGH or the CGH. In some cases, physicians were 
required to cancel and reschedule follow-up appointments due to the pathology reports 
being unavailable. Although this interval was the shortest reported wait ( 19 days), further 
investigation should be done as to when the pathology reports are officially completed 
and signed. Some speculation existed on the validity of these reported wait times. To the 
knowledge of the investigator, no other study has examined this wait interval. 
5.2.4 Interval IV: Receipt of Pathology Report to Patient Informed of Results 
This interval illustrates how differences in urology practices in St. John's can 
affect prostate cancer care wait times. Even though the median wait was relatively short 
compared to other intervals, men with prostate cancer were 2.15 times more likely to 
have met the wait time benchmark than men who did not have cancer. However, only 
15.8% of men actually met the locally established benchmarks. In some practices, there 
was little evidence in the charts to suggest that men who were not diagnosed with cancer 
were scheduled for a follow-up visit. Therefore, it is understandable to see how men with 
prostate cancer were more likely to have met this benchmark. According to local 
urologist Dr. Chris French (personal communication, May 16, 2011 ), men who are not 
seen for a follow-up are typically informed by telephone of their biopsy results. Our data 
suggests this practice is effective for shortening wait times for rural patients and for 
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keeping costs low for patients who otherwise would need to travel long distances for such 
appointments. Further investigation should look at whether phoning patients and 
potentially giving a cancer diagnosis by phone has an impact on quality of life. Dr. 
French noted that men from rural areas are often unable to attend the clinic and require a 
phone call to inform them of the biopsy results. Moreover, due to the urologists' heavy 
clinical caseload, patients that do not require further care under their supervision are 
typically discharged and managed by the patients' family physician who would also 
inform patients of their negative biopsy results and manage their care. However, one of 
the study limitations is that we could not capture data on how long it took patients to see 
their GP for biopsy results. 
Some differences in practice affected this wait interval among urologists. Some 
urologists would book a follow-up appointment on the day ofbiopsy regardless of the 
result, where others would wait until receiving the results. These variations in practice 
may be attributed to the common delays experienced by urologists when waiting for the 
pathology report. In almost 25% of cases, urologists were faced with waiting longer to 
receive proper diagnoses due to pathology reports being sent out for second opinion. 
No other Canadian study has explored the wait time for the interval between 
receipt of pathology report to the patient being informed of results. Literature suggests 
that waiting extended periods of time can have a deleterious effect on the health of men 
awaiting diagnosis due to psychological stress (Saad et al. , 2006; Siemens et al. , 2005; 
Derrett et al. , 1999; Spurgeon, Barwell, and Kerr, 2000). Further research should 
examine the differences between men waiting longer for diagnoses than other men in NL. 
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Source of delays within the lab system are perhaps different from those within the 
clinical care system. Lab work flow may indeed not in any way related to patient 
characteristics by design and our data supports this assumption as this wait interval is not 
related to age, urgency, or community of residence. 
5.2.5 Interval V: Decision to Treat to First Treatment 
A significantly larger proportion of men who met the benchmark were old 
(59.2%), had a low PSA (75.5%), were early-stage (56.5%), had low clinical-risk (59.2%) 
and low Gleason scores (59.2%), and chose watchful waiting (53.1 %) for their first 
treatment. After controlling for predictors, older men were 5.82 times more likely to 
have met the benchmark than younger men. Men with a medium Gleason score were 
5.00 times less likely (0.20 as likely) to have met the benchmark than men with a low 
Gleason. About two-thirds of all men did not meet either the local or provincial 
benchmarks for this interval. In some cases this may be explained by older men choosing 
a watchful waiting treatment option and not choosing a more invasive treatment which 
would most certainly diminish the waiting period compared to those who proceed on to 
further treatment. 
The Department of Health and Community Services ofNL reported (2012) that 
the median and 901h percentile wait time for general curative radiation was 14 and 26 
days respectively. In contrast, our findings suggest that prostate cancer patients are 
waiting significantly longer than reports by the provincial government. As a result, 
informing men that waiting for curative radiation can take up to a month (26 days) can be 
extremely misleading for prostate cancer patients. Moreover, the province does not 
differentiate between different types of cancer when reporting the wait time data. Above 
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all, reporting on this interval only reflects a small fraction of what men experience while 
waiting for prostate cancer care in NL. 
Delays during this interval were not uncommon. In fact, in nearly 15% of cases, 
men required more time to contemplate their treatment options causing a further delay in 
their overall wait time. Interestingly, older men were more than five times more likely to 
have met the local benchmarks than younger men. This result may be explained by older 
men with cancer were less likely to choose surgery (RP) than young men, and were more 
likely to chose watchful waiting in consultation with the urologists, which dramatically 
decreased their waits (Appendix I). Lu-Yao et al. (2009) reported that older men 
diagnosed with prostate cancer rarely die from prostate cancer and chose a less invasive 
treatment option like watchful waiting. We defined the watchful waiting first treatment 
date as the day patients decided on this treatment option. In many cases, this was the 
same day men were informed of their results, which significantly reduced their wait 
times. 
It was not unusual for men to travel outside of the province for brachytherapy and 
return to NL for follow-up. At this time, brachytherapy is not offered as a treatment 
option for men diagnosed with prostate cancer in NL. Further research should explore 
whether this would be a desired treatment option for urologists and men diagnosed with 
prostate cancer in NL. 
In a CIHI (2011) report, the NL provincial government reported that 94% of 
patients are meeting the benchmark for radiotherapy. However, variations still exist 
among provinces with respect to how they are defining the wait interval, which 
contributes to the uncertainty surrounding the data. Moreover, reporting on only one 
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interval of wait can be misleading for the total waiting time a patient may experience 
before radiation therapy. 
5.2.6 Interval VI: GP Referral to Notification of Results 
The majority of men (83.6%) with suspected prostate cancer did not meet the 
local benchmarks, and waited a median of 154 days. Our results suggest that older men 
were more than three times more likely to meet the benchmarks than younger men. PSA 
remains one of the main reference points for how men are triaged, and older men were 
more likely to have a medium to high PSA score, thus resulting in faster waiting periods 
(Appendix 1). Considering older men are more likely to have non-life-threatening slow 
growing prostate cancer, further examination of why older men are triaged for earlier 
diagnosis should take place. Our results also suggest that men who encountered a 
systematic delay for biopsy results were less likely to have met the benchmarks. Further 
examination should take place as to how the pathology reports are being managed. 
Men in NL waited a median of 154 days compared to men in Calgary who 
experienced a median of 46 days (Kavanagh et al. , 2008). Some of the differences 
between these studies may be accounted for because the urologists in the Kavanagh study 
fast tracked patients between GP and urologists. In 2004, Maul et al. presented research 
at the American Urological Association annual conference suggesting that a wait longer 
than three months may significantly increase the risk of biochemical reoccurrence. 
Although they defined their benchmark from diagnosis to radical prostatectomy, our 
study suggests that men from NL are clearly waiting longer than three months and are 
possibly at increased risk for biochemical reoccurrence following therapy. 
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5.2.7 Interval VII: GP Referral to First Treatment 
As depicted in Figure 1, the GP referral to first treatment interval encompasses all 
of the preceding intervals and as a result, indicates the total wait time that men may wait 
for prostate cancer care. Based on the chart review, men seeking urological care waited 
an overall median of six months (188 days) for care from referral to time offirst 
treatment. These results suggest little evidence of triaging and interestingly, older men 
were 3.53 times more likely to have met the benchmark than younger men. This can be 
explained by the fact that a greater percentage of older men having prostate cancer 
choose to have less invasive treatments, which resulted in less waiting. 
Comparing our findings to a Canadian study that looked at similar intervals 
(Kavanaugh et a!., 2008), our study reported that wait times were longer at all intervals 
except the median wait between diagnoses and radical prostatectomy (RP). Another 
Canadian study by Cole eta!. (20 11 ), recently described wait times for all intervals of 
urological care from GP to surgical treatment. Although this study did not look 
specifically at prostate cancer, men from NL experienced longer wait times at all 
intervals, with the exception of the decision to treat to first treatment interval. 
In the diagnosis to surgery (RP) interval, Esmail and Walker (2005) and Simens et 
a!. (2005) reported a median wait of 42 days and 91 days respectively, compared to men 
in NL waiting 46.5 days. Shorter median waits exist in NL between diagnosis and 
surgery (RP) compared to Nam eta!. (2003) who reported 68 days. Unfortunately, due to 
a lack of a consistent definition of wait time intervals for prostate cancer, data from this 
study could not be compared to other Canadian research studies on wait times for prostate 
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cancer (Simonovic et al., 2001; Simonovic et al. , 2005; Cancer Care Ontario, 2004; 
Stevens et. al. , 201 0). 
Comparing results from this study to studies in the United States, in all but one 
study, men from NL waited longer from biopsy and diagnosis to surgery (radical 
prostatectomy) (Boorjian et al., 2005; Lee et al. , 2006; Moul et al. , 2004). Findings also 
suggest that NL men experience shorter waits from GP referral to first treatment than 
men from the UK (Subramanian, Puranik, & Mufti, 2003). 
Although wait time definitions vary (due to study designs and data availability), 
there is a clear lack of consistency on the reporting ofthe full spectrum ofwait times 
across Canada and internationally, making it difficult to make important comparisons. 
5.3 Objective II: Differences Related to Variables oflnterest 
We examined the differences in wait times related to community of residence, 
urgency and age. Our results suggest that little triaging is taking place based on urgency 
and age. In fact, in the decision to treat to first treatment interval, older men were more 
than five times likely to have met the benchmark than younger men. However, this result 
is still complicated by those patients choosing watchful waiting and those patients who 
go on to further treatment naturally encounter a delay in their management. 
Evidence suggests that in the decision to biopsy to biopsy interval, urologists in 
NL are triaging rural residents more urgently than urban residents. This is likely due to 
the inevitable burden rural patients face when accessing specialized care from their rural 
community and traveling long traveling distances to consult with a urologist. According 
to local urologist Dr. Chris French (personal communications, November 10, 201 0), this 
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is common practice among urologists in St. John's for urologists' rural patients. Our 
results suggest that rural patients indeed wait longer from GP referral to first visit with 
the urologist; however, our data also suggest that triaging is taking place from decision to 
biopsy to date of biopsy for rural patients. This practice has diminished the wait times 
experienced by rural patients with suspected prostate malignancy. 
5.4 Study Strengths 
This study has a number of strengths. First, the literature supporting cancer wait 
times in NL is limited, especially for prostate cancer. This study examines the entire 
prostate cancer care pathway, which has not been previously explored in NL. The results 
identify gaps in the delivery of specialized care in NL and can be used to identify 
strategies to improve the timeliness of specialist care in the province. Findings will also 
provide the groundwork for ongoing monitoring and interprovincial comparisons. 
Second, this study begins to inform specialists on current wait times for their patients. 
With the exception of one interval, urologists in NL have little idea about how long men 
are waiting for prostate cancer care. 
Methodologically, this study was made robust as urologists in St. John' s, NL 
reviewed and agreed upon the benchmarks used in our primary analyses based on their 
clinical knowledge and expertise in urological care. Moreover, a presentation was made 
to the genitourinary tumor board rounds at the Health Science Centre in St. John's, NL 
where both radiation and medical oncologists provided feedback on the study design. 
Finally, the study followed the recommendations by the Western Canada Wait 
List Project for moving towards the development of standard definitions of wait times for 
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prostate cancer care. This will allow other researchers and provinces to make valuable 
and accurate comparisons of their wait time data. 
5.5 Study Limitations 
Even though men from rural areas were captured in the study, the study sample 
may not be representative of all prostate cancer wait times in NL. Our study involved six 
urologists based in St. John's, NL at the Health Science Centre and did not encompass the 
practice of the two remaining urologists working in the west coast of the province. 
The chart audit method relies on the urologists dictating important information 
into patients' charts. In some cases, patients' referral, follow-up, and other appointment 
dates were unavailable due to communication taking place informally over the phone. 
Moreover, the chart audits were unable to capture the data for the wait time interval 
between when a patient makes a request for an appointment with the GP until the first 
consultation occurs. We were also unable to capture the information on how patients 
were triaged by the GPs. 
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CHAPTER6 
SUMMARY, IMPLICATIONS AND RECOMMENDATIONS 
6.1 Summary 
Wait times have been the focus of the provinces across Canada throughout the last 
decade. In 2004, Canada's First Ministers met and identified five priority areas for a 
reduction in wait times. Cancer care was one of the top priority areas identified with the 
goal for each province to reduce those wait times by 2007. Benchmarks were established 
in December, 2005 and NL began reporting on those wait times through press releases 
from the Ministry of Health and Community Services. The latest press release suggests 
that waiting for radiotherapy treatment in NL may take up to 28 days; however, this does 
not represent how long a patient may wait throughout the entire care pathway. At this 
time, there are no nationally recognized definitions for measuring wait times in Canada, 
nor a standardized measure to report wait times (e.g. mean, median, or 901h percentile). 
Therefore, making comparisons of the data and informing the public on realistic waiting 
times for care remains difficult. 
This study, employed quantitative methods to examine wait times for prostate 
cancer care in NL. A chart audit was used to review every man who had a prostate 
biopsy in St. John's, NL between April!, 2009- March 31,2010 at the Health Science 
Centre. 
Key findings from the study included: 
1. When compared to wait time benchmarks set by local experts, surgical 
committees, and governments, patients in Newfoundland and Labrador 
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wait longer than recommended during most intervals in the prostate cancer 
care pathway. 
2. The longest wait existed between the GP referral and the first visit with the 
urologist ( 68 days [0, 31 0.0]). Patients experienced a median wait time of 
188 days (35.0, 491.0) from GP referral to first treatment (all modalities). 
3. Even though the majority of people were found to have not met the 
benchmarks in our analysis, our results suggest some triaging of patients 
based on residency (rural patients seen faster between decision to biopsy 
to biopsy). 
4. There appeared to be little evidence to suggest that urologists were 
triaging patients based on age or urgency throughout the prostate cancer 
care pathway. 
5. Patients in Newfoundland and Labrador are waiting longer periods than 
provincially generated reports currently indicate. 
Knowledge of the current wait times for prostate cancer in NL can be used to provide the 
groundwork for ongoing monitoring and interprovincial comparisons while identifying 
strategies to improve the timeliness of specialist care in the province. 
6.2 Implications for Future Research 
This study begins to provide wait time data that reflects more accurately the wait 
times patients experience when accessing the health care system for prostate cancer care 
in the province of Newfoundland and Labrador. The data suggests key areas within the 
care pathway that clinicians, provincial health authorities, and policy makers may focus 
on to improve patient wait times, in particular, the period from when the patient first 
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accesses a general practitioner to the time when the patient first sees the urologist. Since 
the completion of this study, NL has seen a loss of full-time practicing urologists, which 
may result in longer waiting periods to see a urologist for patients with suspected 
malignancy. Further research is needed to: (a) examine in greater detail the disparities 
that may exist between urban and rural patients and patients with and without a family 
doctor; and (b) the impact of different referral practices among primary care medical 
providers. 
Retrospective chart audit remains the most feasible methodological approach to 
studying wait times but data completeness was an issue in this study, as it has been in 
other studies. Most studies examining wait times for prostate cancer illustrated internally 
consistent results; however comparable wait time definitions still remain elusive. 
Moreover, suggestions for improving the quality of data available on paper and electronic 
charts are provided below in the discussion of implications of the study for medical 
practice. 
6.3 Recommendations for Practice 
Recommendations for practice emerging from this study include: 
I. Develop a standardized referral system for general practitioners (GPs). 
The interval between GP referral to first visit with the urologist was the 
longest wait in the prostate cancer care pathway. Evidence suggests there 
is a lack of triaging taking place based on age, community of residence, 
and urgency. Referral letters ranged from informative to vague 
description of the patients' symptoms. A standardized referral system may 
not only shorten wait times at this interval, but could allow the urologists 
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to triage men who have more urgent symptoms of prostate cancer and 
decrease the likelihood of a delay. Currently, a similarly desired 
standardized referral fom1 exists for men being referred by urologists to 
medical oncologists for treatment to ensure that the necessary infonnation 
including the pathology report, radiological investigations, and other 
important clinical infonnation is included to alleviate any delays in NL. 
2. Inform rural men upon referral to a urologist about the likelihood of 
same-day biopsies and offer information about the procedure. This study 
highlighted that rural men were triaged faster between decision to biopsy 
and date of biopsy due to the likelihood of same-day biopsies. Offering 
rural men infonnation about the procedure may allow them to prepare 
psychologically for the procedure and decrease the stress level patients 
may expenence. 
3. Further examine how the pathology reports are managed. During the 
interval between biopsy and receipt of the pathology report, one-quarter 
(25%) of all reports encountered a systematic delay - more commonly due 
to the pathology report unavailable for the urologi st, which later became a 
significant predictor in detennining whether or not men met the 
benchmark between GP referral and notification of results. This study's 
results suggest no specific triaging of these reports. In many cases 
pathology specimens were sent out of province for second opinion or for 
further review which may have caused longer delays to patients care. 
According to the clinical notes, some urologists at times were unable to 
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proceed with the next appointment due to the (un) availability of the 
biopsy reports. Some speculation existed on the validity of these reported 
wait times. Further studies should explore how these biopsies are 
managed and reported. 
4. Offer a follow-up appointment to all men regardless of biopsy result. 
Practices among urologists differed greatly regarding the wait time 
between receipt of pathology report to notification of results. Our study 
highlighted that some men were not seen in the clinic after a negative 
biopsy result due to either the patients' or urologists ' circumstances. 
Patients' symptoms such as an elevated PSA may be due to other 
urological conditions such as BPH and may require further care from the 
urologist. A follow-up appointment with the urologist may improve 
patient continuity of care. The option of having urologists sending the GP 
a negative pathology report with suggestions for further management 
should be explored. 
5. Further investigate the expansion ofbrachytherapy as a treatment option. 
Our study found that interstitial brachytherapy was a desired treatment 
option nearly 7% of the time. Patients who decide on brachytherapy are 
required to leave the province for Ontario to receive this treatment. 
Further examination of the demand for and feasibility of offering this 
treatment option in the province is necessary. 
6. Move towards standardizing definitions, monitoring, and reporting on 
relevant wait times to the public. Men waiting for prostate cancer care are 
9 1 
experiencing lengthy wait times in the prostate cancer care pathway, 
which are not regularly reported by the province. Moreover, reporting 
only on radiotherapy does not capture nearly three-quarters of men 
diagnosed with prostate cancer. Comparing wait times with other 
provinces and current literature remains difficult due to the lack of 
nationally recognized definitions for measuring wait times in Canada, as 
well as, a standardized measure to report on those wait times. 
7. Future research to examine the biochemical recurrence in men 
undergoing definitive therapy for clinically localized prostate cancer. Our 
results suggested the majority of men are not meeting the locally 
established benchmarks and it would be important for future studies to 
examine if any delays were related to the recurrence of prostate cancer. 
8. Improve the quality of data available on paper and electronic charts. 
Consistent inclusion of referral letters, key dates, patient characteristics, 
comorbidities, and patient decisions on treatment should be included in the 
clinical notes. Our study revealed a great deal of variation among 
urologists' clinical notes ranging from highly comprehensive to general. 
Moving towards developing a standard of reporting in the paper and 
electronic charts may improve ability to assess wait time data for future 
studies. 
This study found that men seeking care for suspected or confirmed prostate cancer 
in Newfoundland and Labrador might experience lengthy delays throughout the care 
pathway. Although provincial reporting suggests men with cancer are waiting a month 
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(28 days) for treatment, men with prostate cancer can experience median waits of 188 
days ranging from 35 to 491 . Where comparisons could be made to other areas across 
Canada, men from Newfoundland and Labrador usually waited longer at all intervals 
throughout the care pathway. With the exception of one benchmark, the majority of men 
did not meet the locally established benchmarks. Although efforts have focused on 
improving wait times across the province, increased emphasis should be placed on the 
longer waiting periods such as GP referral to first consultation with the specialist. 
Additionally, future initiatives should be made to target and triage men with more urgent 
symptoms or signs of prostate cancer. 
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APPENDIX A 
Chart Audit and Review Form 
Study ID: _______ _ Date: _______ _ 
104 
Date of Birth: 
----------------
Hospitalization #: ____________ _ 
Community of Residence: 
----------------
Referral Reason: 
------------------------------------------------------
Key Dates Date 
General practitioner referral 
First visit with the urologist 
Decision to biopsy/TRUS 
Date of biopsy/TRUS 
Date pathology report received 
Date patient was informed of results 
Decision of first treatment 
First treatment date 
Patient Attributes Description 
PSA on referral 
DRE findings 
Prostate volume 
Gleason score 
Prostate cancer [J Yes Cl No 
Clinical stage of cancer 
Season upon referral !JSpring CJSummer CJFall CJWinter 
Delays or Cancellations Reason 
First visit with the urologist 
[J Yes Cl No 
Decision to biopsy/TRUS 
[J Yes Cl No 
Date of biopsy/TRUS 
[J Yes Cl No 
Date pathology report received 
[J Yes Cl No 
Date patient was informed of results 
[J Yes Cl No CJ Person Cl Phone 
Decision of first treatment 
[J Yes Cl No 
First treatment 
[J Yes Cl No 
F1rst treatment modality: 
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0 Chemotherapy 
0 Radiation 
0 Surgery 
0 Palliative Care 
0 Watchful Waiting 
0 Other 
Comorbidities: 
Additional Comments: 
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APPENDIX B 
Dependent Study Variables, Categories, and Code Groups 
Dependent Study Variables, Categories, and Code Groups 
Dependent Variables Cate2ories Code Group 
Referral from GP to fust visit with the urologist Met benchmark 1 
Did not meet benchmark 0 
Decision to biopsy to date of the biopsy Met benchmark 1 
Did not meet benchmark 0 
Date of biopsy to date the pathology report received Met benchmark 1 
Did not meet benchmark 0 
Date the pathology report received to the date the Met benchmark 1 
patient was informed of the results Did not meet benchmark 0 
Decision to treat to fust treatment* Met benchmark 1 
Did not meet benchmark 0 
Referral to notification of results Met benchmark 1 
Did not meet benchmark 0 
Referral to first treatment* Met benchmark I 
Did not meet benchmark 0 
•These are benchmarks based on expert opinion ofDr. Chris French. He is a urologist located in St. John's, 
NL 
*Includes individuals with cancer only 
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APPENDIX C 
Independent and Covariate Study Variables, Categories, and Code Groups 
Independent and Covariate Study Variables, Categories, and Code Groups 
Variables Categories Code Groups 
Community of Residence Urban ( ;::!.0 000) 0 
Rural {<10 000) 1 
Age Young{< 70) 0 
Old {:2::70) 1 
Season On Referral Spring 0 
Summer 1 
Fall 2 
Winter 3 
Referral Reason DRE/PSNFamily History 0 
Urinary Problems 1 
Prostate Volume Normal ( <30 cmj) 0 
Abnormal (;so cm3) 1 
Digital Rectal Exam (ORE) Normal 0 
Abnormal 1 
Prostate Specific Antigen (PSA) on Low ( < 10 ng/ml) 0 
Referral Medium (10-1 9.9 ng/mJ) I 
High ( ;;::20 ng/rnJ) 2 
Had Diabetes No 0 
Yes 1 
Had Cardiovascular Disease (CVD) No 0 
Yes 1 
Had Musculoskeletal Condition No 0 
Yes 1 
Had Gastrointestinal Disease/Hernia No 0 
Yes 1 
Had Hypertension No 0 
Yes 1 
Had Other Comorbidity No 0 
Yes I 
Had Prostate Cancer* No (no cancer) 0 
Yes (has cancer) 1 
Clinical Risk* Low-risk (PSA < I 0, <T2b, Gleason <7) 0 
Medium-risk (PSA 10-19.9, T2b, Gleason 7) 1 
High-risk (PSA ;;::20, >T2b, Gleason >7) 2 
Stage of Cancer* Early-stage (PSA < 10, g'2b, Gleason <7) 0 
Late-stage (PSA :2::10, >T2b, Gleason '8) 1 
Gleason* Low {<7) 0 
Medium (7) 1 
High {>7) 2 
Delay in General Practitioner Patient delay 0 
Referral to First Visit with Urologist Physician delay 1 
System delay 2 
No delay 3 
Delay in Decision to Biopsy to Patient delay 0 
Biopsy Physician delay I 
System delay 2 
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No delay 3 
Delay in Biopsy to Receipt of Patient delay 0 
Pathology Report Physician delay I 
System delay 2 
No delay 3 
Delay in Receipt of Pathology Patient delay 0 
Report to Patient Informed of Results Physician delay 1 
System delay 2 
N o delay 3 
Delay in Patient Informed to Patient delay 0 
Decision to First Treatment* Physician delay 1 
System delay 2 
No delay 3 
Delay in Decision to Treat to First Patient delay 0 
Treatment* Physician delay I 
System delay 2 
No delay 3 
*Includes individuals with cancer only 
109 
APPENDIX D 
Characteristics of Men who ar e Young and Old 
Appendix D shows the characteristics of men who were considered young and 
old. Compared to older men, a significantly larger proportion of young men had an 
abnormal (not normal) DRE, a low PSA, did not have diabetes, chose radical 
prostatectomy as a first treatment, and encountered no delay between decision to biopsy 
to date ofbiopsy. There were no other significant differences in the characteristics of 
young and old men in the study sample. 
Characteristics of Men who are Young and Old (n=341) 
Characteristics Young Old p-value 
n (%) n (%) 
Community of residence 0.605 
Urban (?!0 000) 138 (49.6) 29 (46.0) 
Rural (<10 000) 140 (50.4) 34 (54.0) 
Season on referral 0.576 
Spring 61 (21.9) 17 (27.0) 
Summer 70 (25 .2) II (17.5) 
Fall 64 (23.0) 16 (25.4) 
Winter 83 (29.9) 19 (30.2) 
Referral reason 1.000 
PSAIDRE/Family 274 (98.6) 62 (98.4) 
Other 4 (! .4) I ( 1.6) 
Prostate volume 0.388 
Normal ( <30cm3) 52 (35.1) 9 (27.3) 
Not normal ( ;:30cm3) 96 (64.9) 24 (72.7) 
DREa 0.001 
Normal 62 (22.3) 3 (4 .8) 
Not normal 216 (77.7) 60 (95.2) 
PSA0 on referral 0.000 
Low ( < 10 ng/ml) 245 (88.1) 38 (60.3) 
Medium (10-19.9 ng/m1) 23 (8.3) 17 (27.0) 
High ( ;:::20 ng/ml) 10 (3.6) 8 (12.7) 
Had diabetes 0.01 7 
No 261 (93 .9) 53(84.1) 
Yes 17 (6.1) 10 (15.9) 
Had CVDc 0.118 
No 171 (61.5) 32 (50.8) 
Yes 107 (38.5) 31 (49.2) 
Had musculoskeletal condition 0.843 
No 130 (67.4) 31 (68.9) 
Yes 63 (32.6) 14 (31.1) 
Had Gl/Hemiad 0.151 
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No 233 (83.8) 48 (76.2) 
Yes 45 (16.2) 15 (23.8) 
Had hypertension 0.360 
No 250 (89.9) 59 (93.7) 
Yes 28(10.1) 4 (6.3) 
Had other comorbidity 0.746 
No 264 (95.0) 61 (96.8) 
Yes 14 (5.0) 2 (3 .2) 
Has prostate cancer* 0.093 
No - No Cancer 156 (56.1) 28 (44.4) 
Yes- Has Cancer 122 (43.9) 35 (55 .6) 
Stage* 0.191 
Low Risk (Gleason :::;6, g2a, PSA < 10) 57 (46.7) 12(34.3) 
High Risk (Gleason >6, >T2a, PSA 2i0) 65 (53 .3) 23 (65.7) 
Clinical risk* 0.575 
Low (g2a) 55 (45 .1) 17 (48.6) 
Intermediate (T2b) 19 (15.6) 3 (8 .6) 
High (>T2b) 48 (39.3) 15 (42.9) 
Gleason* 0.339 
Low (:::;6) 57 (46.7) 12 (34.3) 
Medium (7) 47 (38.5) 15 (42.9) 
High {>7) 18 (14.8) 8 (22.9) 
Treatment modality* 0.000 
Radical prostatectomy 71 (58 .7) 5 (14.3) 
Watchful waiting (includes active surveillance) 16 (13.2) 11 (3 1.4) 
Radiotherapy 29 (24.0) 13 (37.1) 
Other (brachytherapy, palliative care, hormone therapy) 5 (4.1) 6(17.1) 
Delay in GPe referral to first visit with urologist 0.796 
Patient 1 (0.4) 0 (0) 
Physician 1 (0.4) 0 (0) 
System 0 (0) 0 (0) 
No delay 276 (99.3) 63 (100.0) 
Delay in patient decision to biopsy to biopsy 0.012 
Patient 0 (0) 1 ( 1.6) 
Physician 0 (0) 1 ( 1.6) 
System 0 (0) 0 (0) 
No delay 278 (100.0) 61 (96.8) 
Delay in biopsy to receipt of pathology report 0.422 
Patient 0 (0) 0 (0) 
Physician 0 (0) 0 (0) 
System 66 (23.7) 18 (28.6) 
No delay 212 (76.3) 45 (71.4) 
Delay in pathology report to patient informed of results 0.461 
Patient I (0.4) 0 (0) 
Physician 0 (0) 0 (0) 
System 1 (0.4) 1 (1.6) 
No delay 276 (99.3) 62 (98.4) 
Delay in patient informed to decision to treat* 0.027 
Patient 46 (37.7) 4(1 1.4) 
Physician 1 (0.8) 0 (0) 
System 5 ( 4.1) 2 (5.7) 
No delay 70(57.4) 57 (82.9) 
Delay in decision to treat to treatment* 0.1 20 
Ill 
Patient 8 (6.6) 0 (0) 
Physician 0 (0) 0 (0) 
System 0 (0) 0 (0) 
No delay 114(93.4) 35 ( 1 00.0) 
a DRE - Digital Rectal Examination 
b PSA - Prostate Specific Antigen 
c CVD - Cardiovascular Disease 
ct GI - Gastrointestinal Disease 
e GP - General Practitioner 
*Only patients who have prostate cancer 
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APPENDIXE 
Characteristics of Men from an Urban and Rural Community 
Appendix E shows the characteristics of men from urban and rural communities. There 
were no significant differences in the characteristics of urban and rural residents in the 
study sample. 
Characteristics of Men from an Urban and Rural Community (n=341) 
Characteristics Urban Rural p-
n (% ) n (%) value 
Age 0.605 
Young (<70) I38 (82.6) I40 (80.5) 
Old (?10) 29(17.4) 34 (19.5) 
Season on referral 0 .7 I 7 
Spring 38 (22.8) 40 (23.0) 
Summer 40 (24.0) 4 I (23 .6) 
Fall 43 (25.7) 37 (21.3) 
Winter 46 (27.5) 56 (32.2) 
Referral reason 0.686 
PSAIDREIF amity I65 (98.8) 171 (98.3) 
Other 2 {1 .2) 3 ( 1.7) 
Prostate volume 0.404 
Normal ( <30cm3) 26 (30.6) 35 (36.5) 
Not normal ( ;80cm3) 59 (69.4) 61 (63 .5) 
DRE• 0.550 
Normal 34 (20.4) 31 {17.8) 
Not normal I33 (79.6) 143 (82.2) 
PSAb 0.061 
Low ( < I 0 ng/mi) 144 (86.2) 139 (79.9) 
Medium ( I 0- 19.9 ng/ml) 19 (1 1.4) 21 (12.1) 
High ( ~0 ng/rnl) 4 (2.4) 14 (8.0) 
Had diabetes 0 .090 
No 158 (94.6) 156 (89.7) 
Yes 9 (5.4) 18 {10.3) 
Had CVDc 0.898 
No 100 (59.9) 103 (59.2) 
Yes 67 (40.1) 7 I (40 .8) 
Had musculoskeletal condition 0.689 
No 75 (66.4) 86 (68.8) 
Yes 38 (33.6) 39 (3 1.2) 
Had GVHernia0 0.457 
No 135 (80.8) 146 (83 .9) 
Yes 32 {19.2) 28 (I6.1) 
Had hypertension 0.224 
No 101 (89.4) I 05 (84.0) 
Yes I2 {10.6) 20 {16.0) 
Had other comorbidity 0 .551 
No 158 (94 .6) 167 (96.0) 
Yes 9 (5.4) 7 (4.0) 
Has prostate cancer* 0 .847 
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No - No Cancer 91 (54.5) 93 (53.4) 
Yes- Has Cancer 76 (45.5) 81(46.6) 
Stage* 0.139 
Early-stage (Gleason ~6, g'2a, PSA < 10) 38 (50.0) 31 (38.3) 
Late-stage (Gleason >6, >T2a, PSA ;::10) 38 (50.0) 50 (61.7) 
Clinical risk* 0.099 
Low (g'2a) 38 (50.0) 34 (42.0) 
Intermediate (T2b) 6 (7.9) 16 (19.8) 
High (>T2b) 32 (42.1) 31 (38.3) 
Gleason* 0.237 
Low (~6) 38 (50.0) 31 (38 .3) 
Medium (7) 25 (32.9) 37 (45 .7) 
High (>7) 13 (17.1) 13 (16.0) 
Treatment modality* 0.500 
Radical prostatectomy 37 (49.3) 39 (48.1) 
WatchfUl waiting (includes active surveillance) 16 (21.3) 11 (13.6) 
Radiotherapy 17 (22.7) 25 (30.9) 
Other (brachytherapy, palliative care, hormone therapy) 5 (6.7) 6 (7 .4) 
Delay in GP referral to first visit with urologist 0.368 
Patient 1 (0.6) 0 (0) 
Physician 0 (0) 1 (0.6) 
System 0 (0) 0 (0) 
No delay 166 (99.4) 173 (99.4) 
Delay in patient decision to biopsy to biopsy 0.381 
Patient 0 (0) 1 (0.6) 
Physician 0 (0) 1 (0.6) 
System 0 (0) 0 (0) 
No delay 167 (100.0) 172 (98 .9) 
Delay in biopsy to receipt of pathology report 0.591 
Patient 0 (0) 0 (0) 
Physician 0 (0) 0 (0) 
System 39 (23.4) 129 (74.1) 
No delay 128 (76.6) 129 (74.1) 
Delay in pathology report to patient informed of results 0.207 
Patient 1 (0.6) 0 (0) 
Physician 0 (0) 0 (0) 
System 2 (1.2) 0 (0) 
No delay 164 (98.2) 174 (100.0) 
Delay in patient informed to decision to treat 0.509 
Patient 28 (16.8) 22 (12.6) 
Physician 1 (0) 0 (0) 
System 3 (1.8) 4 (2.3) 
No delay 135 (80.5) 148 (85 .1) 
Delay in decision to treat to treatment* 0.526 
Patient 3 (3.9) 5 (6.2) 
Physician 0 (0) 0 (0) 
System 0 (0) 0 (0) 
No delay 73 (96.1) 76 (93 .8) 
a DRE - Digital Rectal Examination 
b PSA - Prostate Specific Antigen 
c CVD - Cardiovascular Disease 
d GI - Gastrointestinal Disease 
*Includes individuals with prostate cancer only 
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Research Pro roval Committee of Eastern Health 
Eastern 
Health 
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Mr. Taylor Ferrier 
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Health Sciences Centre 
300 Prince Philip Drive 
St. John's, NL 
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Dear Mr. Ferrier: 
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Your research proposal HIC # 10. 118: "Prostate cancer: Wait times to see a Urologist'; was 
reviewed by the Research Proposals Approval Committee (RPAC) of Eastern Health at its 
meeting on September 14, 2010, and we are pleased to inform you that the proposal has been 
granted full approval. 
The approval of this project is subject to the following conditions: 
• The project is conducted as outlined in the HIC approved protocol; 
• Adequate funding is secured to support the project; 
• In the case of Health Records, efforts will be made to accommodate requests based 
upon available resources. If you require access to records that cannot be 
accommodated, then additional fees may be levied to cover the cost; 
• A progress report being provided upon request. 
If you have any questions or comments, please contact Donna Bruce, Manager of the Patient 
Research Centre at 777-7283. 
Sincerely, 
Mike Doyle, PhD 
Director of Research 
Chair, RPAC 
cc: Ms. Donna Bruce, Manager Patient Research Centre 
MD/jmps 
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